STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE HOSPITAL - A PROSPECTIVE OBSERVATIONAL STUDY

By

Dr.GURRAM KAMALAKAR



DISSERTATION SUBMITTED TO SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH TAMAKA, KOLAR, KARNATAKA

In partial fulfilment of the requirement or the degree of

DOCTOR OF MEDICINE IN PAEDIATRICS

Under The Guidance Of

Dr.SUDHA REDDY V R
Professor and HOD
Department of Paediatrics
SDUMC, KOLAR



DEPARTMENT OF PAEDIATRICS
SRI DEVARAJ URS MEDICAL COLLEGE, TAMAKA, KOLAR,
KARNATAKA-563101

JULY 2024

DECLARATION BY THE CANDIDATE

I HEREBY DECLARE THAT THIS DISSERTATION ENTITLED

"STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN

NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE

HOSPITAL - A PROSPECTIVE OBSERVATIONAL STUDY" IS A

BONAFIDE AND GENUINE RESEARCH WORK CARRIED OUT BY ME

UNDER THE GUIDANCE OF DR. SUDHA REDDY V.R. PROFESSOR &

HOD, DEPARTMENT OF PAEDAITRICS, SRI DEVARAJ URS MEDICAL

COLLEGE, KOLAR, KARNATAKA.

Date:

SIGNATURE OF THE CANDIDATE

Place: Kolar

Dr GURRAM KAMALAKAR

ii

CERTIFICATE BY THE GUIDE

THIS IS TO CERTIFY THAT THE DISSERTATION ENTITLED "STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE HOSPITAL – A PROSPECTIVE OBSERVATIONAL STUDY" IS A BONAFIDE AND GENUINE RESEARCH WORK CARRIED OUT BY DR. GURRAM KAMALAKAR IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE DEGREE OF M.D IN PAEDIATRICS, SDUMC, KOLAR

DATE:

PLACE: KOLAR

SIGNATURE OF THE GUIDE Dr. SUDHA REDDY V R

PROFESSOR AND HOD
DEPARTMENT OF PAEDIATRICS
SRI DEVARAJ URS MEDICAL
COLLEGE, TAMAKA, KOLAR.

ENDORSEMENT BY THE HOD, PRINCIPAL / HEAD OF THE INSTITUTION

THIS IS TO CERTIFY THAT THE DISSERTATION ENTITLED, "STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE HOSPITAL – A PROSPECTIVE OBSERVATIONAL STUDY" IS A BONAFIDE AND GENUINE RESEARCH WORK CARRIED OUT BY DR. GURRAM KAMALAKAR UNDER THE GUIDANCE OF DR. SUDHA REDDY V R PROFESSOR AND HOD, DEPARTMENT OF PAEDIATRICS, SRI DEVARAJ URS MEDICAL COLLEGE, KOLAR, IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE DEGREE OF M.D IN PAEDIATRICS, SDUMC, KOLAR

Dr.SUDHA REDDY V R

Dr.K.PRABHAKAR

PROFESSOR AND HOD,

DEPARTMENT OF PEDIATRICS,

SDUMC, KOLAR

PROFESSOR AND PRINCIPAL SDUMC, KOLAR

COPYRIGHT

DECLARATION BY THE CANDIDATE

I HERE BY DECLARE THAT SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH, TAMAKA, KOLAR, KARNATAKA SHALL HAVE THE RIGHTS TO PRESERVE, USE AND DISSEMINATE THIS DISSERTATION / THESIS IN PRINT OR ELECTRONIC FORMAT FOR ACADEMIC / RESEARCH PURPOSE

Date: DR.GURRAM KAMALAKAR

Place: Kolar

©Sri Devaraj Urs Academy of Higher Education and Research, Karnataka



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION & RESEARCH

SRI DEVARAJ URS MEDICAL COLLEGE

Tamaka, Kolar

INSTITUTIONAL ETHICS COMMITTEE



Members

- Dr. D.E.Gangadhar Rao, (Chairman) Prof. & HOD of Zoology, Govt. Women's College, Kolar
- 2. Dr. Sujatha.M.P, (Member Secretary), Prof. Department of Anesthesia, SDUMC
- 3. Mr. Gopinath Paper Reporter, Samyukth Karnataka
- Mr. G. K. Varada Reddy Advocate, Kolar
- Dr. Hariprasad S,
 Assoc. Prof
 Dept, of Orthopedics, SDUMC
- 6. Dr. Abhinandana R
 Asst. Prof.
 Dept. of Forensic Medicine,
 SDUMC
- Dr. Ruth Sneha Chandrakumar Assoc. Prof. Dept. of Psychiatry, SDUMC
- Dr. Usha G Shenoy, Asst. Prof., Dept. of Allied Health & Basic Sciences SDUAHER
- Dr. Munilakshmi U
 Asst. Prof. Dept. of Biochemistry, SDUMC
- 10.Dr.D.Srinivasan, Assoc. Prof. Department of Surgery, SDUMC
- Dr. Waseem Anjum, Assoc. Prof. Department of Community Medicine, SDUMC
- Dr. Shilpa M D
 Assoc. Prof. Department of Pathology, SDUMC

No. SDUMC/KLR/IEC/ 252a /2022-23

Date: 20.07.2022

PRIOR PERMISSION TO START OF STUDY

The Institutional Ethics Committee of Sri Devaraj Urs Medical College, Tamaka, Kolar has examined and unanimously approved the synopsis entitled "Study of clinical profile and outcome of sepsis in neonatal intensive care unit in a tertiary care hospital-A prospective observational study" being investigated by Dr. Gurram Kamalakar & Dr. Sudha Reddy V R in the Department of Pediatrics at Sri Devaraj Urs Medical College, Tamaka, Kolar. Permission is granted by the Ethics Committee to start the study.

Member Secretary
Member Secretary
Institutional Ethics Communication

Institutional Ethics Committee Sri Devaraj Urs Medical College Tamaka, Kolar. Charman CHAIRMAN Institutional Ethics Consisted Sri Devaraj Urs Medical College Tamaka, Kolar



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION & RESEARCH

Tamaka, Kolar 563103

Certificate of Plagiarism Check

| Title of the Thesis/Dissertation | STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE HOSPITAL- A PROSPECTIVE OBSERVATIONAL STUDY |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Name of the Student | DR. GURRAM KAMALAKAR |
| Registration Number | 21PD1082 |
| Name of the Supervisor / Guide | DR. SUDHA REDDY V. R. |
| Department | PAEDIATRICS |
| Acceptable Maximum Limit (%) of Similarity (PG Dissertation) | 10% |
| Similarity | 9% |
| Software used | Turnitin |
| Paper ID | 241859472 |
| Submission Date | 18/07/2024 |

Signature of Student

Signature of Guide/Supervisortrics

Prof & HoD of Paetingtrics

SDUMC, Tamaka, Kolar,

Prof & HoD of Paediatrics SDUMC, Tamaka, Kolar,

University Librarian Sanor Librarian ULLRC, SDUAHER Tamaka, KOLAR-563103

PG Coordinator Sri Devaraj Urs Medical College Tamaka, Kolar-563103

turnitin (1)

Digital Receipt

This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information regarding your submitted in the received your paper. information regarding your submission.

The first page of your submissions is displayed below.

Submission author: Dr. Gurram Kamalakar

Assignment title: PG Dissertation - 2024

Submission title: STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN N...

File name: RY_CARE_HOSPITAL-_A_PROSPECTIVE_OBSERVATIONAL_STUD...

File size: 204.35K

Page count: 48

Word count: 9,285

Character count: 54,201

Submission date: 18-Jul-2024 12:18PM (UTC+0530)

Submission ID: 2418593472

INTENSIVE CARRESTIT IN A TENTIARY CARE HOSPITAL: A PROSPECTIVE

ABSTRACT

Prof & HoD of Paediatrics SDUMC, Tamaka, Kolar,

Copyright 2024 Turnitin. All rights reserved.

Turnitin - Originality Report - STUDY OF CLINICAL PROFILE.

Document Viewer

Turnitin Originality Report

Processed on: 18-Jul-2024 12:19 IST ID: 2418593472 Word Count: 9285 Submitted: 1

STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPS... By Dr. Gurram Kamalakar

| | | | Similarity Index | Internet Sources: 5% Publications: 8% Student Papers: 2% mode: quickview (classic) report | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| | include quoted include bi | ibliography excluding | natches < 10 words | mode. quarter | - |
| pri | int refresh download | | | | _ |
| | 2% match (U.V., Jomily. University of Health Scie U.V., Jomily. "Epidemiloc of Health Sciences (India | gical and Clinicobacteri | inicobacteriological Stu ological Study of Neona | idy of Neonatal Sepsis", Rajiv Ga atal Sepsis", Rajiv Gandhi Univer | indhi sity¤ |
| | 1% match (Internet from https://www.ijbamr.com | m 29-Sep-2022) n/assets/images/issues | /pdf/March%202018% | 20256-269.pdf.pdf | n |
| | <1% match () Arundadhi, M. "Correlati Sepsis with Special Refe Isolates at CMCH", 2016 | erence to the Bacteriolo | Calcitonin and Blood Cu gical Profile and Anti-M | lture in <u>Diagnosis of Neonatal</u> licrobial Susceptibility Pattern of | El the |
| - | <1% match (Internet fro http://repository-tnmgro | | | 7 | 12 |
| | Blood Culture for Suspec Rajiv Gandhi University Mutalik, Seeta. "A Comp Culture for Suspected For Gandhi University of Hea | cted Early Onset Sepsi of Health Sciences (In parative Study of Umbi arly Onset Sepsis in Pr aith Sciences (India), | s in Preterm Neonates : dia), 2023) ical <u>Cord Blood Culture</u> eterm Neonates at Risk | Blood Culture and Peripheral Ve at Risk- A Hospital Based Study" and Peripheral Veno's Blood - A Hospital Based St. 27". Raij | nous |
| | <1% match (Internet fro https://ijpediatrics.com/ | /index.php/ijcp/article/ | | | LAR _S 5 |
| | A A I to attended Tool | tensive Care Unit (NIC | Profile of Late Onset S | Late Onset Sepsis in Neonates of Health Sciences (India), 202 epsis in Neonates Admitted to ciences (India), 2021 | 1) |
| • | <1% match (Internet fro https://medpulse.in/Htm | om 15-Dec-2023) | | | 23 |
| | <1% match (N., Sindu. | | | | |
| - | N., Sindu. "Utility of Vari Gandhi University of Hea | "Utility of Various Herr niversity of Health Scic ious Hematological Par alth Sciences (India), | ameters in Early Detec | in Early Detection of Neonatal | п |
| - | N., Sindu. "Utility of Vari Gandhi University of Hea <1% match (Durga, Div Tertiary Care Centre", R Durga, Divya. "Clinical P Centre", Rajiy Gandhi Ur | "Utility of Various Hern niversity of Health Sciences Hematological Paralth Sciences (India), and a "Clinical Profile and a give Gandhi University of Health Sciences of niversity of Health Sciences | ameters in Early Detect 023 d Outcome of Acute Kid of Health Sciences (Ind Acute Kidney Injury in nees (India), 2023 | tion of Neonatal Sepsis", Rajiv Iney Injury in Neonatal Sepsis in Jia), 2023) Neonatal Sepsis in a Tertlary Ca | a |
| | N., Sindu. "Utility of Vari Gandhi University of Hea <1% match (Durga, Div Tertiary Care Centre", R. Durga, Divya. "Clinical P. Centre", Rajiv Gandhi Ur <1% match (Mevundi, O Sepsis", Rajiv Gandhi Ur Mevundi, Gonesh Neelat Gandhi University of Hea | "Utility of Various Herr niversity of Health Scie ious Hematological Paralth Sciences (India) rya. "Clinical Profile an- ajiv Gandhi University profile and Outcome of niversity of Health Sciencesh Neelappa. "Plat niversity of Health Sciences, "Plat niversity of Health Sciences, "Platelet Count are alth Sciences (India) | ameters in Early Detection 23 d Outcome of Acute Kid of Health Sciences (Ind. Acute Kidney Injury in these (India), 2023 elet Count and Their Inces (India), 2023) d Their Indices as a March 1988 | tion of Neonatal Sepsis", Rajiv Iney Injury in Neonatal Sepsis in Jia), 2023) Neonatal Sepsis in a Tertiary Ca Indices as a Marker of Neonatal Parker of Neonatal Sepsis", Rajiv | a re 🖪 |
| | N., Sindu. "Utility of Vari Gandhi University of Hea <1% match (Durga, Div Tertiary Care Centre", R. Durga, Divya. "Clinical P. Centre", Rajiv Gandhi Ur <1% match (Mevundi, G. Sepsis", Rajiv Gandhi Ur Mevundi, Gonesh Neelat Gandhi University of Hea <1% match (Internet fro https://www.jcdr.net//ai 709xbissue=11&page=5 | "Utility of Various Herniversity of Health Sciences (India) rya. "Clinical Profile anajiv Gandhi University of Health Sciences (India) Gonesh Neelappa. "Plainiversity of Health Sciences (India) "Platelet Count arallth Sciences (India) om 05-Apr-2024) rticle_fulltext.asp?id=: SC10&volume=17&yes | ameters in Early Detect 223 d Outcome of Acute Kid of Health Sciences (Ind Acute Kidney Injury in ences (India), 2023 elet Count and Their In nces (India), 2023) d Their Indices as a Ma 2023 87128issn=0973- | tion of Neonatal Sepsis", Rajiv Iney Injury in Neonatal Sepsis In Iia), 2023) Neonatal Sepsis In a Tertiary Ca Indices as a Marker of Neonatal | a re 🖪 |
| | N., Sindu. "Utility of Vari Gandhi University of Hea <1% match (Durga, Div Tertiary Care Centre", Ri Durga, Divya. "Clinical P Centre", Rajiv Gandhi Ur <1% match (Mevundi, G Sepsis", Rajiv Gandhi Ur Mevundi, Gonesh Neelan Gandhi University of Hea | "Utility of Various Herniversity of Health Sciences (India) rya. "Clinical Profile anajiv Gandhi University rofile and Outcome of niversity of Health Sciences (India) sonesh Neelappa. "Platiniversity of Health Sciences (India) path Sciences (India) om 05-Apr-2024) rticle fulltext.asp?id=: SC10&volume=17&yea | ameters in Early Detect 023 d Outcome of Acute Kid of Health Sciences (Ind Acute Kidney Injury in ences (India), 2023 elet Count and Their In cos (India), 2023) d Their Indices as a Ma 023 87128issn=0973- r=2023 | tion of Neonatal Sepsis", Rajiv Iney Injury in Neonatal Sepsis in Jia), 2023) Neonatal Sepsis in a Tertiary Ca Indices as a Marker of Neonatal Parker of Neonatal Sepsis", Rajiv | a re Ø |

ix

ACKNOWLEDGEMENT

I would like to thank God for giving me the opportunity, strength, and courage throughout the post-graduation and to complete my dissertation.

I express my heartfelt and humble gratitude to my beloved guide **Dr.SUDHA REDDY V R**, HOD and Professor, Department of Paediatrics who hand picked this topic for me and graced study officially with her constant support and expert advice, her encouragement, wise constructive judgment the painstaking effort to weed out errors and her affection during course of study leaves me permanently indebted to her.

I express my deep sense of gratitude and humble thanks to my senior Professors, Dr.Krishnappa.J., Dr.KNV Prasad, Dr. Narendra, DR.James Daniel S, Dr.Srikanth for their advice and encouragement throughout the study.

My heartfelt thanks to Assistant Professors Dr.Bhanuchand P, Dr.Karthik, Dr.Abhishek for their practical tips, invaluable advice and constant encouragement. I would like to thank my senior Residents Dr.Bindu, Dr Jayashree, Dr Pravallika, Dr. Parimala, Dr.Manasa, Dr.Shrishail for their guidance and support.

I extend my sincere thanks to my beloved senior **Dr.Bindu T** for supporting me throughout. I extend my sincere thanks to all seniors **Dr.Mathumitha**,

Dr.Jefrin, Dr.Nikitha, Dr.Trishali, Dr.Prakash, Dr.Praveen for sharing their

immense knowledge. I am thankful for their valuable guidance and helping me

with my dissertation.

I would like to express my gratitude to my close friends Dr.Mouna,

Dr.Karthik, Dr.Purna Jyothi, Dr. Sharadhi, Dr.Sai Teja, Dr.Ram Swaroop,

Dr.Jahnavi, Dr.Rana Pratap for their support and love. Heartfelt thanks to my

juniors Dr.Bhargavi, Dr.Deepak, Dr.Manne Teja, Dr.Ashwini, Dr.supreeth,

Dr.Indra, Dr.pravallika, Dr.Akhila, Dr.Deepthi, Dr.Vishaka, Dr.Varsha

and **Dr.Rohith.** I would express my deepest gratitude to my beloved parents

Mr.G.Rajesham, Mrs.Laxmi and my sister Mrs.Sahithya and my brother

Mr.Sainath for constantly believing in me and whose love, blessings made me

the person what I am today.

I would like to thank Mrs.Gayathri, Mr.Jagannath who had helped me in the

clerical work.

Lastly, I would like to express my gratitude to all my interns and nurses of

paediatric ward and patients who were part of this study without whose support

this study wouldn't have been possible.

Date:

DR GURRAM KAMALAKAR

Place: Kolar

χi

LIST OF ABBREVIATIONS

| Glossary | Abbreviations | |
|----------|----------------------------------------|--|
| NS | Neonatal Sepsis | |
| EOS | Early Onset Sepsis | |
| LOS | Late Onset Sepsis | |
| PROM | Premature Rupture Of Membranes | |
| DIC | Disseminated Intravascular Coagulation | |
| NICU | Neonatal Intensive Care Unit | |
| SNICU | Sick Neonatal Intensive Care Unit | |
| IV | Intravenous | |
| VLBW | Very low birth weight | |
| ELBW | Extreme very low birth weight | |
| PDA | Patent Ductus Arteriosus | |
| BPD | Bronchopulmonary dysplasia | |
| CONS | Coagulase negative Staphylococci | |
| HSV | Herpes simplex virus | |
| VZV | Varicella zoster virus | |
| HIV | Human immunodeficiency virus | |
| CRP | C-Reactive Protein | |
| ANC | Absolute Neutrophilic Count | |
| INC | Immature Neutrophilic count | |
| CSF | Cerebrospinal fluid | |
| ESR | Erythrocyte Sedimentation Rate | |

| PCT | Procalcitonin |
|-------|-------------------------------------------------|
| G-CSF | Granulocyte colony stimulating factor |
| IVIG | Intravenous Immunoglobulin |
| GMCSF | Granulocyte Monocyte Colony Stimulating Factors |
| SVET | Single-volume Exchange Transfusion |
| СВС | Complete blood count |
| NVD | Normal Vaginal Delivery |
| LSCS | Lower segment caesarean section |
| IUGR | Intrauterine growth restriction |
| MAS | Meconium aspiration syndrome |
| AKI | Acute kidney injury |
| MODS | Multiple organ dysfunction syndrome |
| DAMA | Discharge against medical advice |
| UTI | Urinary tract infection |

TABLE OF CONTENTS

| S. No | Table of content | Page no |
|-------|----------------------|---------|
| 1 | INTRODUCTION | 1 |
| 2 | AIMS & OBJECTIVES | 3 |
| 3 | REVIEW OF LITERATURE | 4 |
| 4 | MATERIAL & METHODS | 19 |
| 5 | RESULTS | 24 |
| 6 | DISCUSSION | 35 |
| 7 | CONCLUSION | 41 |
| 8 | LIMITATION | 42 |
| 9 | SUMMARY | 43 |
| 10 | BIBLIOGRAPHY | 45 |
| 11 | ANNEXURES | 51 |
| 12 | MASTER CHART | 60 |

LIST OF FIGURES

| S. No | Name of the Figures | Page No. |
|-------|------------------------------------------------------------|----------|
| 1 | Sources of newborn infection | 4 |
| 2 | Flow diagram for collection and analysis of data | 23 |
| 3 | Distribution of neonates based on gender | 24 |
| 4 | Distribution of neonates based on birth weight | 25 |
| 5 | Distribution of neonates based on mode of delivery | 26 |
| 6 | Distribution of neonates based on the blood culture report | 30 |
| 7 | Distribution of neonates based on the NICU stay duration | 33 |
| 8 | Distribution of neonates based on the outcome | 34 |

LIST OF TABLES

| S. No | Table Description | Page No. |
|-------|------------------------------------------------------------|----------|
| 1 | Risk score for predicting NS | 6 |
| 2 | Manroe's Reference Chart | 11 |
| 3 | Mouzinho's Reference Chart for ANC | 11 |
| 4 | Distribution of neonates based on gender | 24 |
| 5 | Distribution of neonates based on birth weight | 25 |
| 6 | Distribution of neonates based on mode of delivery | 26 |
| 7 | Distribution of neonates based on time of onset of sepsis | 27 |
| 8 | Distribution of neonates based on risk factors | 27 |
| 9 | Distribution of cases based on clinical features | 28 |
| 10 | Distribution of neonates based on complications | 29 |
| 11 | Distribution of neonates based on the blood culture report | 30 |
| 12 | Spectrum of organisms isolated from blood culture | 31 |
| 13 | Distribution of cases based on type of sepsis | 32 |
| 14 | Distribution of neonates based on duration of NICU stay | 32 |
| 15 | Distribution of neonates based on their outcome | 33 |

STUDY OF CLINICAL PROFILE AND OUTCOME OF SEPSIS IN NEONATAL INTENSIVE CARE UNIT IN A TERTIARY CARE

HOSPITAL - A PROSPECTIVE OBSERVATIONAL STUDY

ABSTRACT

BACKGROUND: Neonatal sepsis(NS) is defined as a clinical syndrome of bacteraemia with systemic signs and symptoms of infection in the first 4 weeks of life. Sepsis is the commonest cause of neonatal morbidity and mortality. Neonatologists managing NICUs constantly encounter the ongoing challenge of addressing newborn infections due to evolving microbial flora patterns. Understanding the microbiological profile and antimicrobial susceptibility patterns is crucial for paediatricians when selecting the most effective antibiotics for treating neonates with sepsis. ²

OBJECTIVES: To determine the clinical profile of neonatal sepsis in neonates admitted to NICU and Sick Neonatal Intensive Care Unit(SNICU).

METHODOLOGY: This prospective study was done in neonatal intensive care unit at R.L.JALAPPA HOSPITAL. All neonates who were admitted in NICU or SNICU fulfilling the inclusion criteria were included in the study and evaluated for clinical profile of sepsis and outcome.

RESULTS: In the present study, among the 80 neonates, tachypnea was the most prevalent symptom, noted in 57.5% of cases. Blood culture results showed that 25 neonates (31.3%) were tested positive, while 55 neonates (68.8%) tested negative. The most frequently identified organism was Klebsiella species, found in 11 neonates (13.8%). Additionally,

Candida was detected in 5.0% of cases, E. coli in 3.8%, Acinetobacter in 2.5%, and Enterococci in 2.5%. It was observed that 31.25% of neonates had Culture Positive Sepsis (Definitive) while 68.75% had Probable (Clinical) Sepsis.

CONCLUSION: This study focuses on the clinical profile and outcome of neonatal sepsis in a NICU setting, highlighting its substantial burden on neonatal health. Clinical manifestations varied widely, with tachypnea being the most common symptom. Blood culture results highlighted Klebsiella species as the most prevalent pathogen. Despite advances, the high mortality rate underscores the ongoing need for better early detection, prompt intervention, and overall care practices to improve outcomes for newborns affected by sepsis.

INTRODUCTION

INTRODUCTION

"Neonatal sepsis (NS) is defined as a clinical syndrome of bacteraemia with systemic signs and symptoms of infection in the first 4 weeks of life." It covers a range of systemic infections affecting newborns, including septicemia, meningitis, pneumonia, arthritis, osteomyelitis, and urinary tract infections. Sepsis is the commonest cause of neonatal morbidity and mortality.¹

The clinical presentations of NS are nonspecific. This includes symptoms like fever, respiratory distress, lethargy/irritability, convulsions, bulging fontanelles, refusal to feed, jaundice, bleeding, abdominal distension, and temperature dysregulation.²

Early-onset sepsis (EOS) presents within 72 hrs of life, and late-onset sepsis (LOS) presents beyond 72 hours of life.² In EOS maternal genital tract is the source of the infection. Maternal risk factors like premature rupture of membranes (PROM), chorioamnionitis, peripartum fever, urinary tract infection within 2 weeks prior to delivery and prolonged rupture of membranes > 18 hours, multiple gestations, and caesarean sections are associated with increased risk of EOS.²

LOS occurs because of postnatal nosocomial infections or community-acquired infections. The risk factors associated with LOS are prematurity, prolonged invasive interventions like mechanical ventilation and intravascular catheterization, failure of early enteral feeding with breast milk, long duration of parenteral nutrition, hospitalization, surgery, and underlying respiratory and cardiovascular diseases. ²

The spectrum of bacteria which cause NS varies in different parts of the world.

Bacterial infections are the most common cause of morbidity and mortality during the

neonatal period. Fulminant and fatal course of infection may result in complications such as shock, disseminated intravascular coagulation (DIC) and multi-system organ failure.³ This mandates the need for early diagnosis of these life-threatening conditions for timely treatment and a favourable outcome.^{2,3}

Multidrug antibiotic resistance is an emerging problem in Neonatal Intensive Care Unit (NICU) particularly in developing countries. Neonatologists who supervise NICU always face a continuous challenge in managing neonatal infections due to the changing patterns of the microbial flora. The knowledge of the bacteriological profile and its antibiotic sensitivity pattern is of great use to paediatricians in choosing antibiotics optimally to treat neonates with septicaemia. ²

.

AIMS & OBJECTIVES

AIM & OBJECTIVES

- To determine the clinical profile of neonatal sepsis in neonates admitted to NICU and Sick Neonatal Intensive Care Unit (SNICU).
- To determine the complications and outcome associated with neonatal sepsis in neonates admitted to NICU and SNICU.

REVIEW OF LITERATURE

REVIEW OF LITERATURE

Neonatal period is considered the most important age group at all times as newborns are most vulnerable to disease and death. Historically, the probability of death during neonatal period was so high that many traditional practices were postponed until after first week of life, ensuring the probability of child's survival. Also, the quality of life and health as the child grows to adult life is partly determined at this stage. Many avoidable handicaps during childhood like, cerebral palsy, mental subnormality and recurrent seizures have their origin in perinatal period. Septicaemias is a major cause of mortality and morbidity in neonatal period⁴.

Advances in neonatal intensive care have led to improved survival of neonates, but neonatal sepsis continues to be an important cause of morbidity and mortality. Etiology of NS is multifactorial, but the principal sources of newborn infection are mother and nursery environment. During fetal life, the sources of infection are transplacental and ascending intrauterine infection. Improper handwashing, intravenous (IV) access, ventilation, instrumentation all add to the transmission of infection to the neonate in the nursery ⁴ (Figure-1).




Figure-1: Sources of newborn infection

Neonatal Sepsis: It is a clinical syndrome characterized by signs and symptoms of infection with or without accompanying bacteraemia during first month of life. NS incorporates septicaemia, pneumonia, and meningitis. The pathogen gaining access to blood stream may cause overwhelming infection without much localization called septicaemia or may get predominantly localized to lung or meninges. Superficial infections like conjunctivitis and oral thrush are not included under neonatal sepsis. ⁵

Classification: NS can be classified into EOS and LOS depending on the time of onset of symptoms.

EOS: EOS is one which manifests within first 72 hours of life ⁶. It is caused by organisms prevalent in the genital tract of mother either due to rupture of membrane or during passage through birth canal.

Risk factors for EOS:

- 1. Very low birth weight (VLBW) or preterm: Incidence of neonatal sepsis is inversely related to gestational age and birth weight. According to western studies, incidence in preterm is 1:250, while in term babies it is 1:15000⁷. Babies weighing less than 1000gm are called extremely low birth weight (ELBW) and those weighing between1000-1499 gm are called VLBW. The incidence of EOS is nearly ten times greater in an infant with birth weight <1500 gm compared to normal weight babies⁸.
- 2. Febrile illness in the mother within 2 weeks prior to delivery. The associated features of intra amniotic infection are, maternal or fetal tachycardia, uterine tenderness and leukocytosis⁹. Histopathology of the placenta will show chorioamnionitis.
- 3. Foul smelling liquor or meconium-stained amniotic fluid
- 4. Prolonged rupture of membrane >18 hours; prolonged labor (1st stage & 2nd stage ≥24 hours)
- 5. > 3 vaginal examinations or single unclean examination during labor.

- 6. Difficult labor with instrumentation.
- 7. Birth asphyxia and difficult resuscitation. Apgar <6 at 5 minutes for term, and <3 for preterm¹⁰.

Risk Score: Risk score uses the risk factors to predict the likelihood of developing neonatal sepsis in the newborn. It helps the physician to categorize the babies and plan the management. One of the well-studied risk score developed by Parmar is depicted in Table 1.11

Table 1: Risk score for predicting NS

| Risk factor | | Significant score |
|---------------------------------|---|------------------------|
| PROM >24 hours | 1 | 5 or more in normal |
| Unclean per vaginal examination | 2 | weight babies |
| Birth asphyxia | 2 | 2 or more in low birth |
| Foul smelling liquor | 2 | weight babies |
| Maternal intrapartum fever | 2 | |
| Prolonged labor | 1 | |
| Low birth weight | 1 | |

Bacterial Spectrum: In the West, the most common etiological agent for EOS is Group B streptococci (GBS). Other less commonly found organisms are E. coli, Streptococcus viridans and Staphylococcus aureus¹². In India, there is a prevalence of gram negative bacteremia - E.coli, Klebsiella and Enterococcus fecalis ¹³. Isolation of E.coli (30%), Klebsiella (23%) and Staphylococcus aureus (19%) was reported in one of the Indian studies¹⁴. The nature of colonizing agent is determined by the pattern of flora in birth canal and in the environment. Babies born at home are colonized by the organisms from the mother¹⁵. These tend to be community derived and sensitive to commonly used antibiotics. Those organisms also have

limited pathogenicity. One of intestinal organisms acquired by normal babies is Enterobacteria, which is associated with neonatal sepsis. Breast feeding reduces the intensity of colonization by Enterobacteria. Bifidobacteria predominate in breast fed babies^{16, 17}. Bacteria colonizing the gastrointestinal tract play a vital role in maintaining gastrointestinal homeostasis, including digestion and nutrient absorption.

Bifidobacteria is important for postnatal development of GI mucosa and gut associated lymphoid tissue. Colonization of gastrointestinal tract occurs in 1-2 weeks of postnatal age where as that of upper respiratory tract occurs rapidly, and 90% of the infants have positive pharyngeal cultures by 3rd day¹⁸.

LOS: LOS is acquired by nursery environment which is characterized by onset beyond 72 hours of life. VLBW babies are more prone for nosocomial infection which is about 20-25% ¹⁹. Babies in NICU are at greatest risk for becoming colonized by organisms resistant to antibiotics ²⁰. Nursery overcrowding, poor hand washing and contaminated equipment add to the risk of sepsis in the newborn²¹. Contamination of parenteral nutrition solution has been associated with neonatal infection²². Most babies become colonized without becoming infected, but in others various factors related to host and microorganisms result in infection.

Risk factors for LOS: ^{23, 24}

- 1. Weight less than 750g
- 2. Presence of central venous catheter
- 3. Delayed enteral feeding
- 4. Total parenteral nutrition
- 5. Lack of breastfeeding
- 6. Mechanical ventilation
- 7. Necrotizing enterocolitis
- 8. Complications of prematurity

9. Patent Ductus Arteriosus (PDA) 10. Bronchopulmonary dysplasia (BPD) 11. Prior antibiotic use **Etiology of NS:** In general, the common bacterial causes of EOS include 19: a) Group B- streptococcus b) Escherichia coli c) Streptococcus pneumoniae d) Viridans streptococci e) Enterococci f) Haemophilus influenzae g) Neisseria meningitidis h) Neisseria gonorrhoea i) Listeria monocytogenes etc., Of these, Group B- streptococcus and Listeria monocytogenes are usually of maternal origin. The common bacteria causing LOS include¹⁹: a) Staphylococcus aureus b) Coagulase negative Staphylococci (CONS) c) Enterococci d) Citrobacter e) Enterobacter f) Klebsiella pneumoniae

g) Salmonella

Agents that are implicated to cause nosocomial infection include CONS, Escherichia coli, Klebsiella pneumoniae, Salmonella, Enterobacter aerogenes, Pseudomonas, Serratia and Citrobacter.

The non-bacterial causes of neonatal sepsis include: Adeno virus, Cytomegalovirus, Enterovirus, Human Herpes viruses including Herpes simplex virus (HSV) and Varicella zoster virus (VZV), Human immunodeficiency virus (HIV), Parvovirus, Rubella virus, Candida species, Plasmodia, Toxoplasma gondii etc.. Infection acquired by the neonates after discharge are usually community acquired.

Clinical Features of Sepsis: Sepsis in neonates and infants presents with a spectrum of clinical features that can vary widely in severity and presentation. Respiratory distress is frequently observed, ranging from mild tachypnea to severe respiratory failure, particularly in early-onset sepsis (EOS)²⁵. Poor activity is a predominant symptom in late-onset sepsis (LOS).

Other common manifestations include refusal of feed, temperature dysregulation (hypothermia or hyperthermia), bradycardia or tachycardia, and signs of poor perfusion such as shock. Abdominal distention, hepatomegaly, seizures, and jaundice are also noted, along with bleeding manifestations and arthritis in some cases. Additional symptoms may include cyanosis, hypoglycemia (and rarely hyperglycemia), irritability, diarrhea, petechiae, sclerema, arthritis, and hepatosplenomegaly.

Mandal et al in their study on NS reported varying incidences of clinical features among affected infants. Poor activity and refusal of feed were highly prevalent, affecting 82% and 84% of cases, respectively²⁷. Hypothermia was noted in 56% of infants, while respiratory distress and abdominal distention were reported in 50% and 48% of cases, respectively. Hepatosplenomegaly affected 34% of infants, whereas hyperthermia was observed in 14%.

Sclerema and seizures were noted in 22% and 24% of cases, respectively. Jaundice was present in 30% of infants, bronchopneumonia in 36%, and bleeding manifestations in 22%. Less commonly observed were arthritis (6%) and shock (2%).

Investigations in NS:

Blood culture: It is the confirmatory test in NS. Causative pathogen can be readily recovered with 0.5ml of blood in culture bottles²⁸. Blood for culture should be taken from a peripheral vein after thorough cleaning with antiseptic solution and allowing it to dry. This reduces skin contamination to acceptable levels. A pure growth appearing within 24 - 48 hours is always significant ²⁹. Automated blood culture (BACTEC) method is a better culture method as it detects the growth faster.

C-Reactive Protein (CRP): CRP is an acute phase reactant which is a nonspecific marker of inflammation or tissue destruction. It is elevated in bacterial sepsis and meningitis. There is a delay of 10-12 hours from the onset of infection to the rise in CRP ³⁰. Viral infections do not cause rise in CRP ³¹. Serial CRP reading is more informative than single CRP value. On day 1 of illness, it has a sensitivity of 62% and a specificity of 88%, and on day 2 of illness, sensitivity increases to 90% ³².

Platelet count: It is a late indicator of NS. The major mechanism causing thrombocytopenia is increased platelet destruction and considered significant when count is less than one lakh.³⁰

Leukocyte count: Many aspects of leukocyte count have been studied for their predictive value in diagnosing sepsis. Manroe established reference ranges for Absolute Neutrophilic count (ANC), Immature Neutrophilic count (INC) and Immature to total leukocyte count (IT) ratio which is clinically useful³³ – Table 2. For VLBW infants, the reference ranges are available from Mouzinho's charts³⁴ – Table 3.

Table 2: Manroe's Reference Chart

| | Birth | 12hour | 24 hour | 48 hour | 72 hour | >120 hour |
|----------|------------|------------|------------|-----------|----------------------------------------|-----------|
| ANC | 1800- 5400 | 7800-14400 | 7200-12600 | 4200-9000 | 1800-7000 | 1800-5400 |
| INC | <1120 | <1440 | <1280 | <800 | <500 | <500 |
| IT ratio | <0.16 | <0.16 | <0.13 | <0.13 | <o.13< td=""><td><0.12</td></o.13<> | <0.12 |

Table 3: Mouzinho's Reference Chart for ANC³⁴

| Age | Minimum | Maximum |
|----------|---------|---------|
| Birth | 500 | 6000 |
| 18hours | 2200 | 14000 |
| 60 hours | 1100 | 8800 |
| 120 hour | 1100 | 5600 |

Lumbar puncture^{35,36}

Lumbar puncture plays a critical role in the evaluation of neonatal sepsis by obtaining cerebrospinal fluid (CSF) for culture and analysis. It helps differentiate between sepsis and meningitis, guiding targeted antibiotic therapy. Early performance is crucial to prevent complications like neurologic sequelae.

Micro ESR

Micro ESR (Micro Erythrocyte Sedimentation Rate) in neonatal sepsis serves as a rapid screening tool to assess inflammation and infection severity. It provides supplementary information alongside clinical assessment and other diagnostic tests. Elevated Micro ESR

levels suggest an inflammatory response, aiding in early detection and management of neonatal sepsis.

Procalcitonin (PCT)³⁷

PCT levels rise rapidly in response to bacterial infections, aiding in early identification of neonates at risk of sepsis. PCT helps distinguish between bacterial and non-bacterial causes of infection, guiding clinicians in targeted antibiotic therapy. Serial PCT measurements assist in assessing response to treatment, allowing timely adjustments in therapy as needed. Integration of PCT into clinical protocols improves diagnostic accuracy and antibiotic stewardship, enhancing overall management of neonatal sepsis.

Cell markers ³⁸

Granulocyte colony stimulating factor (G-CSF)³⁹

G-CSF levels may increase in response to infection, contributing to the mobilization and activation of neutrophils to enhance the immune response.

Cytokines⁴⁰

Elevated levels of pro-inflammatory cytokines (such as interleukin-6, interleukin-8, tumor necrosis factor-alpha) are associated with systemic inflammation in neonatal sepsis.

Diagnosis of NS

Culture positivity with organism known to cause sepsis is confirmatory of NS. 41

Risk factors associated with poor outcome in sepsis are as follows: 42

- 1. Preterm
- 2. Shock

3. DIC

- 4. Leukopenia < 5000
- 5. Culture positive sepsis

Treatment

Antibiotics

The indiscriminate use of broad-spectrum antibiotics without appropriate blood cultures and the practice of not stopping their use when no infection is documented have resulted in high antibiotic resistance rates amongst organisms isolated in India. The current data published from India suggests, that cefotaxime must be avoided as an empiric antibiotic. There is also high resistance to ampicillin and gentamicin. Some evidence suggests that use of amikacin and piperacillin-tazobactam may have low failure rates. There may be a justification in using cloxacillin if the incidence of Staphylococcus is high in a given set-up. Antibiotics like carbapenems and vancomycin should be treated as reserve drugs and be used only if primary treatment plan fails. ⁴³

The recommended duration of antibiotic therapy for uncomplicated culture positive NS (no meningitis, bone and joint or staphylococcal infections) is 7–10 days. Antibiotics may be stopped at 2–3 days in babies in whom these were started empirically, when cultures and CRP are negative and there is improvement symptomatically. In neonates with meningitis or staphylococcal sepsis, the duration of treatment may be 2–3 weeks and for up to 4–6 weeks in bone infections.⁴³

Adjunct therapies in treatment of sepsis⁴³

- Intravenous Immunoglobulin (IVIG): IVIG therapy is aiming to provide passive immunity against a broad spectrum of pathogens. It functions by neutralizing bacterial toxins, modulating inflammatory responses, and enhancing opsonization and phagocytosis by neutrophils, thereby aiding in pathogen clearance.
- Granulocyte Colony Stimulating Factors (G-CSF) or Granulocyte Monocyte Colony
 Stimulating Factors (GMCSF): G-CSF enhances the production and release of neutrophils from the bone marrow, which are crucial for combating bacterial infections in neonates.
- Single-volume Exchange Transfusion (SVET): SVET aims to rapidly decrease pathogen load and improve the clinical status of neonates with severe sepsis or septic shock. When conventional therapies, including antibiotics and supportive care, are insufficient in managing, it can be considered.

<u>Supportive care:</u> Sepsis is a multiorgan disease that can result in death and disability. Antibiotics alone cannot change the outcome. Supportive care includes ventilation, inotropes, blood products, glucose, and acid-base monitoring and correction, and is the most important determinant of outcome⁴³.

<u>Complications:</u> Sepsis remains the leading cause of neonatal mortality world over. In the acute phase, hypoglycemia, coagulopathy, organ failures like pneumonia, pulmonary hypertension, shock due to myocardial dysfunction and capillary leaks, renal failure and cholestatic jaundice are not uncommon with Gram negative sepsis. Meningitis can result in complications such as hydrocephalus and developmental delay⁴³.

Prevention of sepsis: Sepsis in the neonate can be prevented by promoting exclusive breastfeeding and simple hand hygiene at the household level and also by preventing applications on the umbilical cord during the first few days of life. Hospital acquired infections can be minimized by good hand hygiene, promoting provision of breast milk to sick LBW neonates, good adherence to asepsis protocols and strict antibiotic policy that limits its use when required ⁴³.

Literature from previous studies:

In a study on the bacteriological profile and predictors of death among neonates with blood culture-proven sepsis, Ba-Alwi NA et al., (2022) reported a mortality of 45.4% out of 238 neonates with positive blood culture. There was a significant association between VLBW, hyperglycemia, mechanical ventilation, and high neonatal mortality. They further reported that among the different clinical presentations of NS, lethargy, vomiting, and respiratory distress were found to be frequently associated with neonatal mortality. Gramnegative bacteria and early-onset sepsis were also associated with high neonatal mortality⁴⁴.

Berhane M et al., (2021) in a study on the clinical profile of neonates admitted with sepsis to NICU reported that out of 304 neonates, 195 (64.1%) had clinical evidence of sepsis. They further reported that the three most frequent presenting signs and symptoms were fast breathing (64.6%), fever (48.1%) and altered feeding (39%). Bacterial pathogens were identified in 94.8 % of neonates. Coagulase negative staphylococci (25.7%), staphylococcal aureus (22.1%) and klebsiella (16.5%) were the most isolated bacteria⁴⁵.

In a retrospective study on sepsis profile in NICU, Salama K et al., (2021) observed that out of 153 cases of neonatal sepsis, 41.2% had EOS and 58.8% had LOS. Positive blood culture was detected in 39.8% of neonates and most detected organism was Klebsiella in EOS and CoNS in LOS⁴⁶.

Yet in another study on the clinical and bacteriological profile of neonatal sepsis, Jatsho J et al., (2020) reported a blood culture positivity rate of 14 %. Culture positive EOS was present in 54.5 % of neonates. Prematurity, APGAR < 6, LBW and maternal intrapartum antibiotics showed a significantly increased risk of culture positive EOS⁴⁷.

Rawat D et al., (2020) conducted a study to determine the bacterial spectrum and antimicrobial susceptibility pattern of neonatal septicaemia. Blood culture reports were positive in 53 (15.31%) cases. Commonest clinical presentation of neonates with septicemia was respiratory distress and commonest maternal risk factor was PROM >18 hours. Gram negative septicaemia (55.10%) was encountered more than Gram positive (44.90%). CoNS (38.78%) was the predominant isolate followed by, Klebsiella spp in 34.69% cases. Best overall sensitivity among Gram-negative isolates was to polymyxin B, colistin and meropenem (100%). Gram-positive isolates had highest sensitivity to Linezolid (100 %) and Vancomycin (100%)⁴⁸.

A study on the bacteriological profile of neonatal septicemia and their antibiotic susceptibility pattern was done by Thapa S et al., (2019). Out of 516 specimens, bacterial growth was obtained in 56 specimens (10.8%). Prevalence of EOS was higher (62.5%) in neonates compared to LOS (37.5%). Majority of neonatal septicemia were caused by gram negative isolates (69.6%). The predominant isolates in early onset septicemia were Acinetobacter species (32.1%) and Staphylococcus aureus (16%) and in late onset septicemia it was Staphylococcus aureus (19.6%) and Acinetobacter species (8.9%) ⁴⁹.

In a study on clinical spectrum, bacteriological profile and antibiotic sensitivity pattern in NICU, Kurma et al, (2019) reported that out of 519 neonates, 35.2% had blood culture positivity, among them 65% had EOS, 59 % were preterm and 58.5 % were LBW neonates. They further reported that the major clinical presentation was respiratory distress (31.2%) and

most isolated organisms were Klebsiella pneumonia (34.7%) and Staphylococcus aureus (21.8%)⁵⁰.

In a study on the bacteriological profile and antibiotic susceptibility pattern of culture positive NS in the NICU, Pokhrel B et al., (2018) reported that out of 336 neonates admitted in the NICU, 69 (20.5%) had culture-positive sepsis. The majority were EOS (n = 54, 78.3%) and were among the preterm babies (n = 47, 68.1%). Most bacterial isolates were gramnegative, predominantly the Klebsiella species (n = 23, 33.3%). Klebsiella showed high resistance to commonly used antibiotics such as; Cefotaxime (90.5%), Gentamicin (75%), Ciprofloxacin (76.2%), Ofloxacin (72.2%) and Chloramphenicol (65%). However, they showed good susceptibility to Carbapenems (100%), Colistin (88.8%) and Tigecycline (81.8%). Among cultures with gram-positive species, CONS (n = 14, 20.3%) predominated. CONS showed high resistance to Oxacillin (80%), Cefotaxime (66.7%) and Meropenem (80%) but good susceptibility (100%) to Vancomycin and Linezolid. Prevalence of multidrug-resistant strain was 73.9% ⁵¹.

A study on the common bacterial agents associated with NS and their antibiotic susceptibility pattern was conducted by Shidiki A et al., (2018). They observed that gram positive isolates (82.6%) were found more than gram negative isolates (16.4%). The most common isolates were Staphylococcus aureus (86.9%), Klebsiella pneumonia (60%) and others. Staphylococcus aureus showed resistance against penicillin G, ceftazidime, cephalexin, cefixime, ampicillin, ofloxacine ⁵².

In a study on early detection of neonatal septicaemia along with its infective etiological agent(s) and assessment of antimicrobial sensitivity pattern, Ghosh S et al., (2018) observed that out of 92 neonates, 53 were male and 39 were female. Bad obstetric history (BOH) was present in 23 mothers. Low to VLBW was seen in more than two thirds culture

positive neonates. All neonates (100%) had poor cry, sucking and reflex problems. Culture positivity was present in 55.43% of which bacterial pathogens was detected in 27(52.94%) and fungal agents in 24 (47.05%) cases. Bacterial sepsis was predominantly caused by different gram-negative organisms (66.66%). Klebsiella sp. and Staphylococcus sp. were the principal isolates. Candida was the commonest fungus reported. Klebsiella isolates were most sensitive to cefotaxime and amikacin while Staph. epidermidis isolates were sensitive to Amoxicillin clavulinic acid ⁵³.

Ekwochi U et al., (2018) documented the clinical symptomatology, bacterial profile, and antibiotic sensitivity for newborn sepsis. In all, 1920 newborns were admitted to the Special Care Baby Unit during the study period. Fifty-seven were managed for culture-proven sepsis, resulting in an in-hospital incidence rate of 29.7 per 1000 admitted newborns (95% confidence interval 21.9–37.4). A total 228 newborns were recruited (57 cases and 171 controls; ratio of 1:3). The most common presenting clinical features were fever (84.2%) and depressed primitive reflexes (50.9%). A case-fatality rate of 7.4% was observed. Newborn's place of birth (P = 0.02) and the final outcome (P = 0.004) were significantly associated with the development of sepsis, while gender (P = 0.12), birth weight (P = 0.33), gestational age (P = 0.53), and mode of delivery (P = 0.74) were not. Nearly 60% of the organisms implicated were coliforms, while one-quarter were Staphylococcus aureus. The most sensitive antibiotics were the fluoroquinolones, particularly ciprofloxacin, while amoxicillin, ampicillin, and clindamycin were generally not effective 54 .

MATERIALS & METHODS

MATERIAL AND METHODS

Source of Data: All neonates admitted to NICU and SNICU with sepsis or later who develop

sepsis in NICU and SNICU at R.L. Jalappa Hospital & Research Centre.

Study Design: A Prospective observational study.

Study Period: 1 year 4 months from September 2022 to December 2023.

Method of Collection of Data:

Inclusion Criteria:

All neonates admitted to NICU and SNICU having 1 or more established clinical features

suggestive of sepsis such as fever (temperature >38°C), hypothermia, poor suck, lethargy,

irritability, seizure, apneic spells, respiratory distress, abdominal distention, poor moro reflex,

with or without maternal risk factors (PROM of >12 hours, maternal fever during delivery,

prolonged labour, urinary tract infection, chorioamnionitis and meconium- stained amniotic

fluid).

Exclusion Criteria:

Birth asphyxia

Congenital anomalies

Suspected metabolic disease.

Refusal of parental consent.

Page 19

Sample Size:

The sample size was estimated by using the proportion of death in subjects who had sepsis (9.7%) from the study by Melkamu Berhane et al.⁴⁵ by using the formula

Sample Size =
$$Z1-\alpha /2 \ 2 \ P \ (1-P)$$

d2

 $Z_{1-\alpha/2}$ = is standard normal variate(at 5% type 1 error (P<0.05) it is 1.96 and at 1% type1 error(P<0.01) it is 2.58). As in majority of studies P values are considered significant below 0.05 hence 1.96 is used in formula.

P= Expected proportion in population based on previous studies or pilot studies

d= Absolute error or precision

P = 9.7% or 0.097

q = 90.3 or 0.903

d = 7.5% or 0.075

Using the above values at 95% Confidence level a sample size of 60 subjects were included in the study. Considering 10% Non response a sample size of $60 + 6 \approx$ 66 minimum subjects were included in the study.

Methodology:

• This study was started after obtaining approval from the institutional ethical committee and taking informed consent from parents. All neonates fulfilling the inclusion criteria were included in the study.

- Complete physical examination of neonates was performed.
- After taking informed consent, the following investigations were done for all subjects:
 Complete blood count (CBC), CRP and blood culture.
- The following investigations were done as and when required: Chest X- ray; Neurosonogram; Cerebrospinal fluid (CSF) analysis; Liver function tests; Renal function tests; CT; MRI.
- Based on the results of the investigations, the subjects were divided into 2 groups namely Probable (Clinical) Sepsis and Culture Positive Sepsis (Definitive).
- Neonates were treated as per the institutional protocol and followed up till discharge from the NICU.

For the study purpose following definitions were used:

EOS: Sepsis which manifests within first 72 hours of life and **LOS** is one which manifests beyond 72 hours of life. ⁶

Probable (Clinical) Sepsis: In a neonate having clinical picture suggestive of septicemia, if there was presence of **any one** of the following criteria:

- Positive septic screen
- Presence of predisposing factors (maternal fever or foul-smelling liquor or PROM or gastric polymorphs (>5 hpf)
- Radiological evidence of pneumonia.⁵⁵

Culture Positive Sepsis (Definitive): In a neonate having clinical picture suggestive of septicemia, pneumonia or meningitis with isolation of pathogens from blood or CSF or urine or abscess.⁵⁵

Septic screen was considered positive when 2 or more of the following parameters were

present:55

1. Total leukocyte count: $< 5000/\text{mm}^3 \text{ or } > 24,000/\text{mm}^3$.

2. Absolute neutrophil count: low count as per Monroe chart for term infant and Mouzinho

chart for VLBW infants.

3. Immature or band cells to total neutrophil ratio: >0.2

4. Micro ESR: >15 mm 1st hour

5. CRP: >1mg/dL.

CBC: Venous blood sample (2 ml) was collected in EDTA vacutainer and processed in

Automated Haematology Analyser Sysmex Autoloader Processing.

CRP: Venous blood sample (2 ml) was collected in a sterile tube without anticoagulant and

allowed to clot at room temperature. Serum was separated and stored at $+2^0$ to 4^0 C and

processed in Diagnostic Reagent Kit in the microbiology lab of RLJH&RC, ARKRAY

Healthcare Pvt Ltd.

Blood Culture:

Venous blood sample (at least 1 ml) was collected using aseptic technique in a container

having specific culture media. Bottles were loaded into Bact/ALERT equipment. It was

considered as positive if there was a beep or if the screen showed yellow light and was

considered as negative if the screen showed green after 7 days.

Probable (Clinical) Sepsis
(n=80)

Excluded (n=0)

Consented and enrolled
(n=80)

Data collected and investigation
done for all the 80
neonates

Culture Positive Sepsis
(Definitive) - (n=25)

Analysed for Outcome
(n=80)

Figure 2: Flow diagram for collection and analysis of data

Statistical Analysis:

Data was entered into Microsoft excel data sheet and analysed using SPSS 22 version software. Categorical data was represented in the form of Frequencies and proportions. Chi-square was used as test of significance. Continuous data were represented as mean and standard deviation. Independent t test was used as test of significance to identify the mean difference. P value <0.05 was considered as statistically significant.

RESULTS

RESULTS & OBSERVATIONS

Table 4: Distribution of neonates based on gender (n=80)

| | | Frequency | Percentage |
|--------|--------|-----------|------------|
| Gender | Male | 45 | 56.3 |
| | Female | 35 | 43.8 |
| | Total | 80 | 100 |

Figure 3: Distribution of neonates based on gender




Table 4 & Figure 3 depict the distribution of cases based on gender. It was observed that out of 80 neonates diagnosed with NS, 45 (56.3%) were males while 35 (43.8%) were females.

Table 5: Distribution of neonates based on birth weight (n=80)

| | | Frequency | Percentage |
|--------------|---------------|-----------|------------|
| | <1 kg | 4 | 5.0 |
| | 1- <1.5 kg | 23 | 28.8 |
| | 1.5 - < 2 kg | 36 | 45.0 |
| Birth Weight | 2.0 - <2.5 kg | 11 | 13.8 |
| | >2.5 kg | 6 | 7.5 |
| | Total | 80 | 100 |

Figure 4: Distribution of neonates based on birth weight





Table 5 & Figure 4 depict the distribution of cases based on birth weight. Majority (45%) of neonates were in the birth weight category of 1.5 Kg to <2 Kg. In the birth weight category of 1 Kg to < 1.5 Kg, 23 (28.8%) neonates were present. There were 11(13.8%) neonates in the birth weight category of 2 Kg to < 2.5 Kg. Four (5%) and 6 (7.5%) neonates were in the birth weight categories of < 1 Kg and > 2.5 Kg respectively.

Table 6: Distribution of neonates based on mode of delivery (n=80)

| | | Frequency | Percentage |
|------------------|---------------------|-----------|------------|
| Mode of Delivery | *NVD | 31 | 38.8 |
| | #LSCS | 46 | 57.5 |
| | Assisted Vaginal | 3 | 3.8 |
| | Total | 80 | 100 |

^{*}Normal vaginal delivery; #Lower segment caesarean section

Figure 5: Distribution of neonates based on mode of delivery (n=80)



It was observed that majority (57.5%) of neonates were delivered by LSCS while 31 neonates (38.8%) were delivered through NVD, and 3 neonates (3.8%) were delivered through assisted vaginal methods. (Table 6 & Figure 5)

Table 7: Distribution of neonates based on time of onset of sepsis (n=80)

| Time of onset of sepsis | Frequency | Percentage |
|-------------------------|-----------|------------|
| *EOS | 32 | 40 |
| #LOS | 48 | 60 |
| Total | 80 | 100 |

^{*}Early onset sepsis; #Late onset sepsis

Table 7 depicts distribution of neonates based on time of onset of sepsis. It was observed that 60% of neonates had LOS while 40% had EOS.

Table 8: Distribution of neonates based on risk factors (n=80)

| Risk Factors | Frequency | Percentage |
|-------------------|-----------|------------|
| Central Line | 44 | 55.0 |
| *PROM | 34 | 42.5 |
| #IUGR | 17 | 21.3 |
| ^MAS | 12 | 15.0 |
| Intrapartum Fever | 6 | 7.5 |

^{*} Premature rupture of membranes; # Intrauterine growth restriction; ^ meconium aspiration syndrome

Table 8 depicts distribution of cases based on risk factors. More than half (55%) of the neonates with sepsis had central lines. History of PROM was noted in 34 cases (42.5%), IUGR was seen in 17 (21.3%) and MAS was present in 12 (15.0%) neonates. Maternal history of intrapartum fever was present in 6 (7.5%) cases.

Table 9: Distribution of cases based on clinical features

| Clinical features | Frequency | Percentage |
|-------------------------|-----------|------------|
| Tachypnea | 46 | 57.5 |
| Lethargy | 36 | 45.0 |
| Refusal of feeds | 32 | 40.0 |
| Temperature instability | 32 | 40.0 |
| Abdominal distension | 29 | 36.3 |
| Conjunctivitis | 29 | 36.3 |
| Vomiting | 27 | 33.8 |
| Grunting | 25 | 31.3 |
| Bleeding | 24 | 30.0 |
| Apnea | 22 | 27.5 |
| Sclerema | 21 | 26.3 |
| Seizures | 19 | 23.8 |
| Weak cry | 18 | 22.5 |
| Umbilical sepsis | 7 | 8.8 |

Table 9 depicts the distribution of neonates based on clinical features. It was observed that tachypnea was the most common symptom observed in 46 neonates (57.5%). The other

clinical features noted were lethargy in 36 neonates (45.0%), refusal of feeds and temperature instability in 32 neonates each (40.0%), abdominal distension and conjunctivitis in 29 (36.3%) neonates each, vomiting in 27 (33.8%), grunting in 25 (31.3%), bleeding in 24 (30.0%), and apnea in 22 cases (27.5%). Sclerema was present in 21 neonates (26.3%), seizures in 19 (23.8%), weak cry in 18 (22.5%) and umbilical sepsis in 7 cases (8.8%).

Table 10: Distribution of neonates based on complications


| Complications | Frequency | Percentage |
|------------------|-----------|------------|
| Hypoglycemia | 34 | 42.5 |
| Thrombocytopenia | 32 | 40.0 |
| AKI | 26 | 32.5 |
| MODS | 21 | 26.3 |
| Meningitis | 4 | 5.0 |

Hypoglycaemia was present in 34 neonates (42.5%) and thrombocytopenia in 32 neonates (40.0%). Acute kidney injury (AKI) was seen in 26 cases (32.5%), multiple organ dysfunction syndrome (MODS) in 21 neonates (26.3%) and meningitis in 4 cases (5.0%) – Table 10.

Table 11: Distribution of neonates based on the blood culture report (n=80)

| | | Frequency | Percentage |
|---------------|----------|-----------|------------|
| Blood culture | Positive | 25 | 31.3 |
| | Negative | 55 | 68.8 |
| | Total | 80 | 100 |

Figure 6: Distribution of neonates based on the blood culture report



Out of 80 neonates, blood culture was positive in 25 neonates (31.3%) – Table 11 & Figure 6.

Table 12: Spectrum of organisms isolated from blood culture (n=25)

| | | Frequency | Percentage |
|----------|-------------------------|-----------|------------|
| Organism | | | |
| | Gram Negative organisms | | |
| | Klebsiella pneumoniae | 11 | 44 |
| | E coli | 3 | 12 |
| | Acinetobacter | 2 | 8 |
| | Enterobacter | 1 | 4 |
| | Kleb oxytoca | 1 | 4 |
| | Gram positive organisms | | |
| | Enterococci | 2 | 8 |
| | CONS | 1 | 4 |
| | Fungus | | |
| | Candida | 4 | 16 |
| | Total | 25 | 100 |

Klebsiella species was the most isolated organisms (44%) followed by Candida (16%) and E. coli (12%). Other organisms identified were Acinetobacter and Enterococci in 2 (8%) neonates each. Coagulase-negative Staphylococci (CONS), Enterobacter, and Klebsiella oxytoca were identified in 1 (4%) neonate each – Table 12.

Table 13: Distribution of cases based on type of sepsis (n=80)

| Type of sepsis | Frequency | Percentage |
|--------------------------------------|-----------|------------|
| Probable (Clinical) Sepsis | 55 | 68.75 |
| Culture Positive Sepsis (Definitive) | 25 | 31.25 |
| Total | 80 | 100 |

Tabe 13 depicts type of sepsis based on investigations. It was observed that 31.25% of neonates had Culture Positive Sepsis (Definitive) while 68.75% had Probable (Clinical) Sepsis.

Table 14: Distribution of neonates based on duration of NICU stay (n=80)

| | | Frequency | Percentage |
|------------------|------------|-----------|------------|
| | ≤7 days | 18 | 22.5 |
| | 8-14 days | 30 | 37.5 |
| NICU Stay (Days) | 15-21 days | 25 | 31.3 |
| | >21 days | 7 | 8.8 |
| | Total | 80 | 100 |

Eighteen neonates (22.5%) were in NICU for a duration of \leq 7 days, while 30 neonates (37.5%) stayed for 8 to 14 days. Twenty-five neonates (31.3%), and 7 neonates (8.8%) were in NICU for 15-21 days and >21 days respectively.




Figure 7: Distribution of neonates based on the NICU stay duration

Table 15: Distribution of neonates based on their outcome (n=80)

| | | Frequency | Percent |
|---------|-----------|-----------|---------|
| | Death | 7 | 8.75 |
| Outcome | Recovered | 67 | 83.75 |
| Outcome | *DAMA | 6 | 7.5 |
| | Total | 80 | 100 |

^{*} Discharged against medical advice

Out of 80 neonates with sepsis, 67 (83.75%) recovered while 7 neonates (8.75%) died due to sepsis-related complications. Six neonates (7.5%) were discharged against medical advice for various reasons – Table 15.




Figure 8: Distribution of neonates based on the outcome

DISCUSSION

DISCUSSION

NS is considered the leading cause of infant mortality and morbidity in the NICU. Early diagnosis and therapy are essential for the prevention of morbidity and mortality of NS. The incidence and the causative organisms of sepsis vary from place to place. Knowledge of the bacterial profile and the antibiotic susceptibility pattern of the isolates play an important role in the management of sepsis. The present study was conducted to determine the clinical profile of NS in neonates admitted to NICU and SNICU.

Sepsis and Gender

In this study, a total of 80 neonates diagnosed with sepsis were included. Among these patients, 45 were male, accounting for 56.3% of the sample, while 35 were female, representing 43.8%. This distribution indicates a slight predominance of male neonates. Similar findings were reported by Thapa S et al., ⁴⁹, Pokhrel B et al., ⁵¹, Ghosh S et al., ⁵³, Ekwochi U et al., ⁵⁴, Yadav SK et al., ⁵⁷, Panda PK et al., ⁵⁸. Shrivastava AK et al., ⁶⁰ Devkota K et al., ⁶¹. However, no explanation can be offered for this male preponderance.

Sepsis and Birth weight

In the present study, majority (45%) of neonates were in the birth weight category of 1.5 Kg to <2 Kg. In the birth weight category of 1 Kg to <1.5 Kg, 23 (28.8%) neonates were present. There were 11(13.8%) neonates in the birth weight category of 2 Kg to <2.5 Kg. Four (5%) and 6 (7.5%) neonates were in the birth weight categories of <1 Kg and >2.5 Kg respectively.

In Budhiarta KDL et al., ⁵⁶ found that lower birth weight was associated with higher mortality, particularly in neonates with birth weights less than 2500 grams. Yadav SK et al., ⁵⁷ reported that 45% of the neonates had a birth weight of less than 2.5 kg. Panda PK et al., ⁵⁸

highlighted that preterm and low birth weight neonates had lower discharge rates and higher mortality. Siwakoti S et al., ⁵⁹ reported that 55% of the neonates with culture-positive sepsis had a birth weight of less than 2500 grams. Shrivastava AK et al., ⁶⁰ highlighted that preterm (41.46%) and low birth weight (22.73%) were the most common associated factors in early-onset neonatal septicemia. Devkota K et al., ⁶¹ reported that 25.36% of neonates with sepsis had low birth weight, and 18.12% had very low birth weight. These studies consistently demonstrate that neonates with birth weights below 2500 grams are at increased risk of mortality and sepsis. This highlights the increased vulnerability of preterm and low birth weight infants to serious health complications, particularly early-onset neonatal septicemia.

Sepsis and Mode of delivery

In the present study it was observed that majority (57.5%) of neonates were delivered by LSCS while 31 neonates (38.8%) were delivered through NVD, and 3 neonates (3.8%) were delivered through assisted vaginal methods. Ghosh S et al.,⁵³ reported that 52.18% of neonates were delivered normally, while 47.82% were delivered by caesarean section. Siwakoti S et al.,⁵⁹ found that 32% of neonates with sepsis were born by caesarean section. Similarly, Devkota K et al.,⁶¹ reported that 62.32% of neonates with sepsis were delivered via spontaneous vaginal delivery and while 37.68% were delivered via caesarean section. However, no significant interpretations or conclusions were drawn regarding these differences in delivery methods across the studies.

Time of onset of sepsis

In present study it was observed that 60% of neonates had LOS while 40% had EOS.

Devkota K et al., ⁶¹reported that 71.01% of neonates had early-onset NS, while 28.99% had late-onset NS. In a study conducted by Gurung B et al., ³ among neonates with sepsis, 30.2%

had early onset and 69.8% had late onset neonatal sepsis. Berhane M et al., ⁴⁵ reported that out of 304 neonates, 195 (64.1%) had clinical evidence for sepsis, majority (84.1%) of them having early onset neonatal sepsis.

Sepsis and risk factors

In the present study more than half (55%) of the neonates with sepsis had central lines. History of PROM was noted in 34 cases (42.5%), IUGR was seen in 17 (21.3%) and MAS was present in 12 (15.0%) neonates. Maternal history of intrapartum fever was present in 6 (7.5%) cases. Rawat et al.,⁴⁸ reported various maternal risk factors affecting neonatal septicaemia; rupture of membranes for more than 18 hours was the commonest factor with 63.64% cases followed by foul smelling liquor in 27.27%. febrile illness in mother 18.18% and maternal urinary tract infection (UTI) in 9.09%. Studies conducted by Rawat et al.,⁴⁸ Devkota K et al., ⁶¹ concluded that factors such as low birth weight, prematurity, mechanical ventilation, invasive procedures were the predisposing factors for sepsis in neonates.

Sepsis and Blood culture

In the present study Klebsiella species was the most isolated organisms (44%) followed by Candida (16%) and E. coli (12%). Other organisms identified were Acinetobacter and Enterococci in 2 (8%) neonates each. Coagulase-negative Staphylococci (CONS), Enterobacter, and Klebsiella oxytoca were identified in 1 (4%) neonate each.

In the study by Rawat et al.,⁴⁸ the etiology of bacterial culture-positive isolates comprised Gram-negative bacilli in 55.10% and Gram-positive cocci in 44.90% of cases. The most common isolates were Coagulase-negative Staphylococci (38.78%), Klebsiella spp. (34.69%), Acinetobacter (14.29%), Enterobacter (4.08%), Enterococcus spp. (4.08%), Coagulase-positive Staphylococci (2.04%), and Escherichia coli (2.04%).

Thapa et al.,⁴⁹ reported that the majority (69.6%) of neonatal septicemia cases were caused by gram-negative isolates. Acinetobacter species were the most frequently isolated pathogens (32.1%), followed by Staphylococcus aureus (19.6%). In early-onset septicemia, Acinetobacter species (32.1%) and Staphylococcus aureus (16%) predominated, while in late-onset septicemia, Staphylococcus aureus (19.6%) and Acinetobacter species (8.9%) were most prevalent.

According to Pokhrel et al.,⁵¹ the majority (77%) of bacterial isolates were gram-negative. Klebsiella species, Coagulase-negative Staphylococci (CONS), and Enterobacter were identified as the most common pathogens. However, the blood culture positivity rate in our study is low compared to the results reported by Rawat et al.,⁴⁸Thapa et al.,⁴⁹ and Pokhrel et al.,⁵¹

Sepsis and clinical profile

In the present study it was observed that tachypnea was the most common symptom observed in 46 neonates (57.5%). The other clinical features noted were lethargy in 36 neonates (45.0%), refusal of feeds and temperature instability in 32 neonates each (40.0%), abdominal distension and conjunctivitis in 29 (36.3%) neonates each, vomiting in 27 (33.8%), grunting in 25 (31.3%), bleeding in 24 (30.0%), and apnea in 22 cases (27.5%). Sclerema was present in 21 neonates (26.3%), seizures in 19 (23.8%), weak cry in 18 (22.5%) and umbilical sepsis in 7 cases (8.8%).

Rawat D et al., ⁴⁸ reported respiratory distress (65.30%) as the commonest presentation among culture positive cases followed by encephalopathy (22.44%) and seizures (14.28%). Common clinical findings observed by Pokhrel B et al.,⁵¹ were respiratory distress (79.7%), tachycardia (60.9%), cyanosis (59.4%) and hypothermia (53.6%). Ekwochi U et al., ⁵⁴ reported fever as the most common symptom, with 84.2% of the presentations manifesting as

such. Poor suckling (39.3%), fast breathing (43.6%), jaundice (39.3%), lethargy (31.6%), and poor cry (30.4%) were other common symptoms, while vomiting (17.5%), diarrhea (1.8%), abdominal distention (15.8%), excessive cry (12.5%), and bleeding from the cord (3.5%) were not very common. Budhiarta KDL et al., ⁵⁶ included common symptoms such as respiratory distress, jaundice, and signs of infection in the clinical profiles of neonates with sepsis. Yadav SK et al., ⁵⁷ emphasized clinical signs like tachypnea, respiratory distress, and abdominal distension as key indicators of sepsis. Siwakoti S et al., ⁵⁹ reported common clinical features such as refusal to feed, fever, jaundice, and respiratory distress. Shrivastava AK et al., ⁶⁰ reported common symptoms such as respiratory distress, fever with jaundice, and poor feeding.

The study observed tachypnea as the most prevalent symptom among neonates (57.5%), with additional common features including lethargy, refusal of feeds, and temperature instability. Other symptoms such as abdominal distension, conjunctivitis, vomiting, grunting, and bleeding were also noted. Comparisons with other studies underscored variations in clinical presentations of neonatal sepsis, highlighting respiratory distress, fever, jaundice, and feeding difficulties as frequent symptoms across different research findings.

Sepsis and Outcome

In the present study, 7 (8.75%) neonates died due to sepsis-related complications. Majority (83.75%) of neonates recovered and were discharged from the NICU. Six neonates (7.5%) were discharged against medical advice (DAMA) due to various reasons. Siwakoti S et al., ⁵⁹ reported an in-hospital mortality rate of 7% among neonates with culture-positive sepsis and Rawat D et al., ⁴⁸ observed a mortality of 10.2% among neonates with sepsis which was almost similar to the findings of our study. Panda PK et al., ⁵⁸ reported a slightly higher mortality rate of 11%. Higher mortality rates of 15.94% and 28.2% were reported by Pokhrel

B et al.,⁵¹ and Budhiarta KDL et al., ⁵⁶ respectively. NS is a major cause of death in low- and middle-income countries. Various characteristics have been reported to be associated with mortality in NS such as sclerema, ELBW, thrombocytopenia, leukopenia and hyperglycemia.⁶²

CONCLUSION

CONCLUSION

This study focuses on the clinical profile and outcome of neonatal sepsis in a NICU setting, highlighting its substantial burden on neonatal health. The findings emphasize the vulnerability of neonates with lower birth weight and stresses the need for careful monitoring and targeted treatments. Clinical manifestations varied widely, with tachypnea being the most common symptom. Blood culture results highlighted Klebsiella species as the most prevalent pathogen. Effective treatment depends on understanding local bacterial types and which antibiotics are effective against them. Despite advances, the high mortality rate underscores the ongoing need for better early detection, prompt intervention, and overall care practices to improve outcomes for newborns affected by sepsis.

LIMITATIONS

- Small sample size.
- The study did not include long-term follow-up of neonates, which is essential to understand the chronic impacts and long-term outcomes of NS.

SUMMARY

SUMMARY

- In this study, a total of 80 neonates diagnosed with NS were included. Among these
 neonates, 45 were male, accounting for 56.3% of the sample, while 35 were female,
 representing 43.8%.
- Among neonates with sepsis, the distribution of birth weights showed that 5.0% weighed < 1 kilogram, 28.8% weighed between 1 and <1.5 kilograms, 45.0% had a birth weight of 1.5 to <2 kilograms, 13.8% weighed between 2 and <2.5 kilograms, and 7.5% had a birth weight > 2.5 kilograms.
- The distribution of delivery modes among neonates with sepsis indicated that 38.8% were delivered via NVD, 57.5% via LSCS, and 3.8% via assisted methods. Cesarean deliveries were predominant, comprising more than half of the cases among neonates affected by sepsis.
- It was observed that 60% of neonates had LOS while 40% had EOS.
- More than half (55%) of the neonates with sepsis had central lines. History of PROM was noted in 34 cases (42.5%), IUGR was seen in 17 (21.3%) and MAS was present in 12 (15.0%) neonates. Maternal history of intrapartum fever was present in 6 (7.5%) cases.
- In the present study, various clinical features were observed among neonates with sepsis. Tachypnea was the most prevalent symptom, noted in 57.5% of cases. Lethargy was observed in 45.0% of neonates, while refusal of feeds and temperature instability were observed in 40.0% each. Other symptoms included abdominal distension and conjunctivitis (36.3% each), vomiting (33.8%), grunting (31.3%), bleeding (30.0%), apnea (27.5%), sclerema (26.3%), seizures (23.8%), weak cry (22.5%), and umbilical sepsis in 8.8% of cases.

- Hypoglycaemia was present in 34 neonates (42.5%) and thrombocytopenia in 32 neonates (40.0%). Acute kidney injury (AKI) was seen in 26 cases (32.5%), multiple organ dysfunction syndrome (MODS) in 21 neonates (26.3%) and meningitis in 4 cases (5.0%)
- Blood culture results showed that 25 neonates (31.3%) were tested positive, while 55 neonates (68.8%) tested negative. The most frequently identified organism was Klebsiella species, found in 11 neonates (13.8%). Additionally, Candida was detected in 5.0% of cases, E. coli in 3.8%, Acinetobacter in 2.5%, and Enterococci in 2.5%.
- It was observed that 31.25% of neonates had Culture Positive Sepsis (Definitive) while 68.75% had Probable (Clinical) Sepsis
- The duration of NICU stay varied among the neonates studied: Eighteen neonates (22.5%) were in NICU for a duration of ≤7 days, while 30 neonates (37.5%) stayed for 8 to 14 days. Twenty-five neonates (31.3%), and 7 neonates (8.8%) were in NICU for 15-21 days and >21 days respectively.
- Out of 80 neonates with sepsis, 67 (83.75%) recovered while 7 neonates (8.75%) died due to sepsis-related complications. Six neonates (7.5%) were discharged against medical advice for various reasons

BIBLIOGRAPHY

REFERENCES:

- Agarwal R, Deorari A, Paul V, Sankar MJ, Sachdeva A. Infections. Neonatal sepsis. In: AIIMS Protocols in Neonatology. 2nd ed. Vol 1. New Delhi: Noble Vision; 2019. p. 303-16.
- 2. Jatsho J, Nishizawa Y, Pelzom D, Sharma R. Clinical and bacteriological profile of neonatal sepsis: a prospective hospital-based study. Int J Pediatr. 2020:1-9.
- Gurung B, Shresta LP. Bacterial profile of Early versus Late onset neonatal sepsis and its antimicrobial susceptibility - A 1-year retrospective study in a tertiary level teaching hospital of Nepal. J Inst Med. 2017;39(3):40-46.
- 4. Mouzinho A, Charles R, Sanchez PJ, Risser R. Child health and nutrition in India. Lancet. 2011; 377:332-36.
- 5. Ghai OP, Paul VK, Baggai A. Essential pediatrics. 10th ed. New Delhi: CBS Publishers and distributors Pvt. Ltd; 2023:136.
- Singh M. Care of the newborn. 8th ed. New Delhi: CBS Publishers and Distributors Pvt. Ltd; 2015.
- 7. Klaus MH, Fanaroff AA. Care of the high-risk neonate. 5th ed. Philadelphia: WB Saunders; 2001:262.
- 8. Cloharty JP, Eichenwald EC, Stark AR. Manual of neonatal care. 6th ed. New Delhi: Wolters Kluwer Pvt. Ltd; 2010:274.
- 9. Klein R. Infectious diseases of the fetus. 7th ed. United States of America: Elsevier; 2011:51.
- 10. Eichenwald EC. Cloherty and Stark's Manual of Neonatal Care. Philadelphia, Pennsylvania: Wolters Kluwer Pvt. Ltd; 2017.
- 11. Neonatal sepsis. Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh. Indian J Pediatr. 1988; 55:946.

- 12. Martin RJ, Fanaroff AA, Walsh MC. Neonatal-perinatal medicine. 9th ed. United States: Elsevier; 2011:794.
- 13. Kuruvilla KA, Pillai S, Jesudason M, Jana AK. Bacterial profile of sepsis in neonatal unit in South India. Indian Pediatr. 1998; 35:851-8.
- 14. Visser MR. Clinical and bacteriological profile of neonatal septicemia. 2002; 39:1038-42.
- 15. Kerr MM, Hatchison JH, McVicar J, Givan J. The natural history of bacterial colonization of newborns in a maternity hospital. Scott Med J. 1976; 21:111-6.
- 16. Blamer SE, Warton BA. Diet and fecal flora in the newborn: Breast milk and infant formula. Arch Dis Child. 1989; 64:1672-77.
- 17. Blaner SE, Scott PH, Warton BA. Diet and fecal flora in the newborn: Casein and whey protein. Arch Dis Child. 1989; 64:1678-84.
- 18. Finelli L, Livengood JR, Saiman L. Surveillance of pharyngeal colonization: Detection and control of serious bacterial illness in low-birth-weight infants. Pediatr Infect Dis J. 1994; 13:854-9.
- 19. Kliegman R, Stanton B, Behrman RE, Geme JWS, Schor NF, editors. Nelson textbook of pediatrics. Philadelphia, PA: Elsevier; 2016
- 20. McCarthy AE, Victor G, Toye B. Risk factors for acquiring ampicillin-resistant enterococci and clinical outcome in a Canadian tertiary care hospital. J Clin Microbiol. 1994; 32:2671-76.
- 21. Fanaroff K. Care of the high-risk neonate. 3rd ed. Philadelphia: Ardmore Medical Books; 2001:366.
- 22. Fleer A, Sanders RC, Visser MR. Septicemia due to coagulase-negative staphylococcus in neonatal intensive care unit: clinical and bacteriological features and contaminated fluids as a source of infection. Pediatr Infect Dis. 1983; 2:426-32.

- 23. Stoll RJ, Hanson R, Fanaff AA. Late onset sepsis in very low birth neonates: the experience of Neonatal Research Network. Pediatrics. 2002; 110:285-91.
- 24. Makhoul IR, Sujov P, Smolkin T. Epidemiologic, clinical and bacteriologic characteristics of late onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics. 2002; 109:34-9.
- 25. Cloharty JP, Eichenwald EC, Stark AR. Manual of neonatal care. 6th ed. New Delhi: Wolters Kluwer Pvt. Ltd; 2010:275.
- 26. Mandal GP, Raghavan M, Bhat BV, Srinivasan S. Neonatal septicemia among inborn and outborn babies in a referral hospital. Indian J Pediatr. 1991; 58:529-33.
- 27. Srinivasan S. Neonatal septicemia among inborn and outborn babies in a referral hospital.

 Indian J Pediatr. 1991; 58:530-4.
- 28. Jawaheer G, Neel TJ, Shaw NJ. Blood culture volume and detection of coagulase-negative staphylococcus septicemia in neonates. Arch Dis Child. 1997; 76:57-58.
- 29. Gladstone IM. A 10-year review of neonatal sepsis and comparison with previous 50 years' experience. Pediatr Infect Dis J. 1990; 9:819-890.
- 30. Mathers NJ, Pohlandt F. Diagnostic audit of CRP in neonatal infection. Eur J Pediatr. 1987:146-147.
- 31. Randel RC, Kearns DB, Nespeca MP, Scher CA, Swayer MH. Vocal cord paralysis as a presentation of intrauterine infection with varicella zoster. Pediatr. 1996; 97:127-8.
- 32. Wagle S, Granang A, Kohan R, Evans SF. CRP as a diagnostic tool in very immature babies. J Child Health. 1994:30-40.
- 33.Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. J Pediatr. 1979; 95:89-98.
- 34. Mouzinho A. Revised reference ranges for circulatory neutrophils in very low birth weight infants. Pediatr. 1994; 94:76-82.

- 35. Baltimore RS. Neonatal nosocomial infection. Semin Perinatol. 1993; 22:25-32.
- 36. Sarff LD, Platt LH, McCracken GH. Cerebrospinal fluid evaluation in neonates: comparison of high-risk neonates with and without meningitis. J Pediatr. 1976; 88:473-7.
- 37. Fjaertoft G, Hakanssen L, Ewald P. Neutrophil CD11b expression as a diagnostic marker of early onset sepsis. Pediatrics. 1998; 42:451-55.
- 38. Kennen C, Overturf G, Bessman S, Sierra. Granulocyte colony stimulating factor as a marker of bacterial infection in neonates. Pediatrics. 1996; 28:769-72.
- 39. Buck C, Dundschn G, Gallat S. Interleukin 6 as a sensitive parameter for early diagnosis of neonatal sepsis. Pediatrics. 1994:54-58.
- 40. Sarff LD, Platt LH, McCracken GH. CSF evaluation in neonates: comparison of high-risk neonates with and without meningitis. J Pediatr. 1976; 88:473-7.
- 41. Ginver LB, Baker CS. The prevention and treatment of neonatal group B streptococcal infection. Pediatr Infect Dis. 1988; 3:65-69.
- 42. Sankar MJ, Agarwal R, Deorari AK, Paul VK. Sepsis in newborn. Indian J Pediatr. 2008; 75:261-66.
- 43. Parthasarathy A, Menon PSN, Nair MKC, editors. IAP textbook of pediatrics. 5th ed. New Delhi: Jaypee; 2013.
- 44. Ba-Alwi NA, Aremu JO, Ntim M, Takam R, Msuya MA, Nassor H, et al. Bacteriological profile and predictors of death among neonates with blood culture-proven sepsis in a national hospital in Tanzania A retrospective cohort study. Front Pediatr. 2022; 10:1-12.
- 45. Berhane M, Gidi NW, Eshetu B, Gashaw M, Tesfaw G, Wieser A, et al. Clinical profile of neonates admitted with sepsis to neonatal intensive care unit of Jimma Medical Center, a tertiary hospital in Ethiopia. Ethiop J Health Sci. 2021;31(3):485-94.

- 46. Salama K, Gad A, El Tatawy S. Sepsis profile and outcome of preterm neonates admitted to neonatal intensive care unit of Cairo University Hospital. Egypt Pediatr Assoc Gaz. 2021;69(1):1-9.
- 47. Jatsho J, Nishizawa Y, Pelzom D, Sharma R. Clinical and bacteriological profile of neonatal sepsis: a prospective hospital-based study. Int J Pediatr. 2020:1-9.
- 48. Rawat D, Barolia PK, Solanki DL, Bakolia H. A clinico-microbiological profile, antimicrobial sensitivity and outcome of neonatal sepsis in NICU, Ajmer. Int J Med Health Res. 2020; 6:32-36.
- 49. Thapa S, Sapkota L. Changing trend of neonatal septicemia and antibiotic susceptibility pattern of isolates in Nepal. Int J Pediatr. 2019:1-7.
- 50. Kurma VR, MS R, Manchu T, Manchu K. Neonatal sepsis: clinical spectrum, bacteriological profile and antibiotic sensitivity patterns in neonatal intensive care unit in a tertiary care hospital. Int J Contemp Med Res. 2019;6(6):1-4.
- 51. Pokhrel B, Koirala T, Shah G, Joshi S, Baral P. Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal. BMC Pediatr. 2018; 18:208.
- 52. Shidiki A, Pandit B, Vyas A. Incidence and antibiotic profile of bacterial isolates from neonatal septicemia in National Medical College and Teaching Hospital, Birgunj, Nepal. J Pharm Technol. 2018:1-5.
- 53. Ghosh S, Basu G. A hospital-based study on clinico-microbiological profile of neonatal septicemia. Asian J Med Sci. 2018;9(2):25-30.
- 54. Ekwochi U, Ifediora C, Osuorah CD. A 4-Year prospective study of clinico-bacterial profile and antibiogram of neonatal bacterial sepsis at a tertiary health facility in a resource-limited setting. J Clin Neonatol. 2018; 7:80-8.

- 55. Tripathi S, Malik GK. Neonatal Sepsis: past, present and future; a review article. Internet J Med Update. 2010;5(2).
- 56. Budhiarta KDL, Kardana IM. Neonatal Profile and Outcome in Neonatal Intensive Care Unit Sanglah Hospital. Am J Pediatr. 2020;6(3):289-294.
- 57. Yadav SK, Giri A. Bacteriological Profile of Neonatal Sepsis in a Neonatal Intensive Care Unit of a Tertiary Care Hospital of Eastern Nepal. J Coll Med Sci-Nepal. 2019;15(1):93-97.
- 58.Panda PK, Panda PK. Clinical profile and outcome of newborns admitted to a secondary level neonatal intensive care unit in tribal region of Odisha. J Clin Neonatol. 2019; 8:155-161.
- 59. Siwakoti S, Sah R, Singh R, Khanal B. Clinical, Bacteriological Profile and Outcome of Neonatal Sepsis. J Nepal Health Res Counc. 2022;20(57):967-972.
- 60.Shrivastava AK, Choudhary PR, Roy SK. Bacteriological profile of neonatal and pediatrics sepsis in intensive care unit at a tertiary care hospital in western India. Int J Contemp Pediatr. 2021; 8:460-466.
- 61.Devkota K, Kanodia P, Joshi B. Sepsis among Neonates Admitted to a Neonatal Intensive Care Unit in a Tertiary Care Centre. J Nepal Med Assoc. 2024;62(270):76-78.
- 62. Apanga DA, Kumbeni MT, Salifu AM, Mireku-Gyimah N, Apanga PA. Predictors of neonatal mortality in the Eastern Regional Hospital in Ghana: A retrospective cohort study. PLOS Global Public Health. 2024: 6;4(6)

ANNEXURE

PATIENT INFORMATION SHEET

Principal investigator: DR.GURRAM KAMALAKAR/DR.SUDHA REDDY V R

I Dr. GURRAM KAMALAKAR, Post graduate student in Department at Sri Devraj

Urs Medical College, will be conducting a study titled "Study of Clinical profile and

outcome of Sepsis in neonatal intensive care unit in a tertiary care hospital-A

prospective observational study, for my dissertation under the guidance of

Dr.SUDHA REDDY V.R, Professor of Department of Paediatrics. The participants of

this study include neonates who are admitting to NICU and SNICU with sepsis or

later who develops sepsis in NICU and SNICU, You will not be paid any financial

compensation for the participation of your child in this research project.

All the data will be kept confidential and will be used only for research purpose by

this institution. You are free to provide consent for the participation of your child in

this study. You can also withdraw your child from the study at any point of time

without giving any reasons whatsoever. Your refusal to participate will not prejudice

you to any present or future care at this institution.

Name and Signature of the Principal Investigator

Contact number:

Date-

ಮಾಹಿತಿ ನೀಡಿದ ಒಪ್ಪಿಗೆ ನಮೂನೆ

ದಿನಾಂಕ:

| ನಾನು, ಶ್ರೀ/ಶ್ರೀಮತಿ |
|----------------------------------------------------------------------------------------------------|
| ನನ್ನ ಮಗುವನ್ನು ನಿರೀಕ್ಷಿತ |
| ವೀಕ್ಷಣಾ ಅಧ್ಯಯನದಲ್ಲಿ ಸೇರಿಸಲಾಗುವುದು ಎಂದು ವಿವರಿಸಲಾಗಿದೆ - ಕ್ಲಿನಿಕಲ್ ಪ್ರೊಫೈಲ್ನ ಅಧ್ಯಯನ ಮತ್ತು ತೃತೀಯ |
| ಆರೈಕೆ ಆಸ್ಪತ್ರೆ-ನಿರೀಕ್ಷಿತ ವೀಕ್ಷಣಾ ಅಧ್ಯಯನದಲ್ಲಿ ನವಜಾತ ತೀವ್ರ ನಿಗಾ ಘಟಕದಲ್ಲಿ ಸೆಪ್ಸಿಸ್ನ ಫಲಿತಾಂಶ, ಈ ಮೂಲಕ |
| ನಾನು ಹೆಮಟೊಲಾಜಿಕಲ್ ಮತ್ತು ಕ್ಲಿನಿಕಲ್ ನಿಯತಾಂಕಗಳ ಅವಲೋಕನಗಳನ್ನು ದಾಖಲಿಸಲು ಯಾವುದೇ ಬಲ ಅಥವಾ |
| ಪೂರ್ವಾಗ್ರಹವಿಲ್ಲದೆ ನನ್ನ ಮಾನ್ಯವಾದ ಲಿಖಿತ ತಿಳುವಳಿಕೆಯನ್ನು ನೀಡುತ್ತೇನೆ. ಒಳಗೊಂಡಿರುವ ಸ್ವಭಾವ ಮತ್ತು |
| ಅಪಾಯಗಳನ್ನು ನನಗೆ ವಿವರಿಸಲಾಗಿದೆ, ನನ್ನ ತೃಪ್ತಿ. ನಡೆಸುತ್ತಿರುವ ಅಧ್ಯಯನದ ಬಗ್ಗೆ ನನಗೆ ವಿವರವಾಗಿ ವಿವರಿಸಲಾಗಿದೆ. |
| ನಾನು ರೋಗಿಯ ಮಾಹಿತಿ ಹಾಳೆಯನ್ನು ಓದಿದ್ದೇನೆ ಮತ್ತು ಯಾವುದೇ ಪ್ರಶ್ನೆಯನ್ನು ಕೇಳಲು ನನಗೆ ಅವಕಾಶವಿದೆ. ನಾನು |
| ಕೇಳಿದ ಯಾವುದೇ ಪ್ರಶ್ನೆಗೆ ನನ್ನ ತೃಪ್ತಿಗೆ ಉತ್ತರಿಸಲಾಗಿದೆ. ನನ್ನ ಮಗುವನ್ನು ಈ ಸಂಶೋಧನೆಯಲ್ಲಿ ಪಾಲ್ಗೊಳ್ಳುವಂತೆ |
| ಅನುಮತಿಸಲು ನಾನು ಸ್ವಯಂಪ್ರೇರಣೆಯಿಂದ ಒಪ್ಪಿಗೆಯನ್ನು ನೀಡುತ್ತೇನೆ. ಇತಿಹಾಸವನ್ನು ಒದಗಿಸಲು, ದೈಹಿಕ ಪರೀಕ್ಷೆಗೆ |
| ಒಳಗಾಗಲು, ಕಾರ್ಯವಿಧಾನಕ್ಕೆ ಒಳಗಾಗಲು, ತನಿಖೆಗೆ ಒಳಗಾಗಲು ಮತ್ತು ಅದರ ಫಲಿತಾಂಶಗಳು ಮತ್ತು ದಾಖಲೆಗಳನ್ನು |
| ಇತ್ಯಾದಿಗಳನ್ನು ವೈದ್ಯರು / ಸಂಸ್ಥೆ ಇತ್ಯಾದಿಗಳಿಗೆ ಒದಗಿಸಲು ನಾನು ಈ ಮೂಲಕ ಒಪ್ಪಿಗೆ ನೀಡುತ್ತೇನೆ. ಶೈಕ್ಷಣಿಕ ಮತ್ತು |
| ವೈಜ್ಞಾನಿಕ ಉದ್ದೇಶಕ್ಕಾಗಿ ಕಾರ್ಯಾಚರಣೆ / ಕಾರ್ಯವಿಧಾನ, ಇತ್ಯಾದಿಗಳನ್ನು ವೀಡಿಯೊ ಗ್ರಾಫ್ ಅಥವಾ ಛಾಯಾಚಿತ್ರ |
| ಮಾಡಬಹುದು. ಎಲ್ಲಾ ಡೇಟಾವನ್ನು ಪ್ರಕಟಿಸಬಹುದು ಅಥವಾ ಯಾವುದೇ ಶೈಕ್ಷಣಿಕ ಉದ್ದೇಶಕ್ಕಾಗಿ ಬಳಸಬಹುದು. |
| ಕಾರ್ಯವಿಧಾನ / ಅಧ್ಯಯನದ ಸಮಯದಲ್ಲಿ ಯಾವುದೇ ಅಹಿತಕರ ಪರಿಣಾಮಗಳಿಗೆ ನಾನು ವೈದ್ಯರು / ಸಂಸ್ಥೆ |
| ಇತ್ಯಾದಿಗಳನ್ನು ಜವಾಬ್ದಾರರನ್ನಾಗಿ ಮಾಡುವುದಿಲ್ಲ. |
| |
| |
| (ಪಿಟಿ. ಅಟೆಂಡೆಂಚ್ನ ಸಹಿ ಮತ್ತು ಹೆಸರು) (ರೋಗಿಯೊಂದಿಗಿನ ಸಂಬಂಧ) |
| ಸಾಕ್ಷಿ: |
| |
| (ಸಂಶೋಧನಾ ವ್ಯಕ್ತಿ/ವೈದ್ಯರ ಸಹಿ ಮತ್ತು ಹೆಸರು) |

INFORMED CONSENT FORM

| Date: | |
|-----------------------------------------------------|------------------------------------------------|
| I, Mr/Mrs | ,have been explained in my own vernacular |
| language that my child will be included in A | Prospective Observational Study-Study of |
| Clinical profile and outcome of Sepsis in neo | natal intensive care unit in a tertiary care |
| hospital- A prospective observational study, | hereby I give my valid written informed |
| consent without any force or prejudice for recor | ding the observations of haematological and |
| clinical parameters . The nature and risks in | volved have been explained to me, to my |
| satisfaction. I have been explained in detail about | ut the study being conducted. I have read the |
| patient information sheet and I have had the op | portunity to ask any question. Any question |
| that I have asked, have been answered to my s | atisfaction. I provide consent voluntarily to |
| allow my child as a participant in this research | a. I hereby give consent to provide history, |
| undergo physical examination, undergo the proc | edure, undergo investigations and provide its |
| results and documents etc to the doctor / institute | e etc. For academic and scientific purpose the |
| operation / procedure, etc may be video graph | ned or photographed. All the data may be |
| published or used for any academic purpose. | I will not hold the doctors / institute etc |
| responsible for any untoward consequences during | ng the procedure / study. |
| | |
| (Signature & Name of Pt. Attender) | (Signature/Thumb impression & |
| | Name of Pt.Attender/Guardian) |
| (Relation with patient) | |
| Witness: | |
| | |
| | (Signature & Name of Research |
| | person/doctor) |

PROFORMA FOR NEONATAL SEPSIS

| UHID: | IP NO: |
|-----------------------------------------------------|---------------|
| NAME: | SEX: |
| GESTATION AGE: WKS | TERM/PRETERM: |
| BALLARD SCORE: | |
| Birth Wt:gm | |
| Wt at admission:gm | |
| Date of Birth | |
| | |
| Date of Admission: | |
| Date of Discharge: | |
| Date of Death: | |
| Duration of stay :days | |
| Self Referral : Y / N | |
| | |
| MATERNAL DELIVERY DATA | |
| 1.Mode of delivery: [1/2/3] [1-Vaginal/2-Assisted/3 | -caesarian] |
| 2. Place of delivery: [1/2] [1-Home/2-Institution] | |
| • Home: [1/2] | |
| [1-Untrained/2-Trained personnel] | |

Institutional: [1/2/3/4/5/6]

[1-HSC/2-PHC/3-Taluk HQ hospital/4-District HQ hospital/5-Tertiaryreferral unit/6-Private Nursing home] Conducted by: [1/2/3/4] [1-Nurse/2-Doctor/3-Obstetrician/4-None] 3. Type of facility Equipment: [1/2/3] [1-Labour room/2-Theatre facilities/3-facilities for neonatal care] MATERNAL RISK FACTORS Birth order [1/2/3/4/5/more] Multiple gestations [Y/N/NK] Intrapartum fever [Y/N/NK] PROM > 18hrs [Y/N/NK]Vaginal examinations >3 in labour [Y/N/NK]Meconium staining: [Y/N/NK] Cloudy amniotic fluid: [Y/N/NK] Foul smelling amniotic fluid: [Y/N/NK] UTI in the last trimester: [Y/N/NK] Maternal Illness: [1/2/3/4/5]

[1-PIH/2-Anaemia/3-Diabetes/4-Heart disease/5-Others]

Maternal education: _____Paternal education: _____

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

NEONATAL RISK FACTORS

| 1. | Birth asphyxia: [Y/N/NK] |
|------|----------------------------------------------------------|
| 2. | Cord status: [1/2/3] [1-Bandage/2-Ointment/3-Dry] |
| 3. | Feeding |
| | a. Feeding pattern [1/2/3] [1-Exclusive/2-Not exclusive] |
| | b. Prelacteal feeds: [Y/N] If Yes specify |
| 4. | Clean clothes: [Y/N] |
| 5. | Bath to the baby: [Y/N] |
| 5. | Home remedies: [Y/N/NK] If Yes specify |
| | |
| CLIN | ICAL EXAMINATION |
| 1. | Superficial infections |
| | • Umbilical sepsis: [Y/N] |
| | • Pyoderma: [Y/N] |
| | • Conjunctivitis: [Y/N] |
| 2. | Apneic spells: [Y/N] |

SYMPTOMATOLOGY

| General | |
|---------|---|
| Ochcia | L |

Temperature

| • Lethargy | |
|------------------------------------|--|
| • Refusal to suck | |
| • Poor cry | |
| • Poor weight gain | |
| • Incessant cry Respiratory System | |
| • Respiratory rate/min | |
| • Chest retractions | |
| • Grunt | |
| • Apnea | |
| Central nervous system | |
| • LOC | |
| • Seizures | |
| Bulging Fontanels | |
| Shock | |

- Fever
- Hypothermia

Gastrointestinal

- Abdominal distention
- Vomiting

Diarrhea

others

- Sclerema
- Bleeding

LABORATORY FINDINGS

Blood culture: [Positive/Negative]

If positive- organism and sensitivity

C-reactive protein:[Positive/Negative]

Peripheral smear studies:

WBC Count: [1/2/3] [1-<5000/2-5000-15,000/3->15,000]IT

Ratio>0.2: [Y/N]

Toxic granules: [Y/N]

OUTCOME

- 1. Recovered
- 2. Expired

FINAL DIAGNOSIS

MASTER CHART

| | | | | | | | | | | | | | | | | | | | | | È | | | | | | | | | | | | |
|------------------|----------------|-------------------|--------|--------------------------|-------------------------------|-----------------|---------------|------------------|------|----------------|----------------------------|-----------------|---------------|-----------|-----------|------------------|-----------|-----------|-----------|-----------|------------------------|------------|-----------|-----------|------------|-----------------|------------------|------------|-------|------------|------------------------|------------------|------------------------|
| UHID | GESTATION | BTWT | GENDER | DOA | MODE OF DELIVERY | PLACE | PROM | INTRAPARTM FEVER | 9511 | CENTRAL LINE | FEEDING | UMBLICAL SEPSIS | CONJUCTIVITIS | APNEA | LETHARGY | REFUSAL OF FEEDS | WEAK CRY | TCHYPNEA | GRUNTING | SEIZURES | EMPERATURE INSTABILITY | DISTENSION | VOMITING | BLEEDING | SCLEREMA | HYPOGLYCEMIA | THROMBOCYTOPENIA | MENINGITIS | SOM | CULTURE | ORGANISM | NICU STAY | OUTCOME |
| 209393 | 37WK 3 D | 2.3 | | 13-03-2023 | NVD | RUH | NO N | O N |) N | O NO | | | | NO | | | | NO | | NO | NO | | | NO | | | | |) NO | NEGATIVE | | 8DAYS | RECOVERED |
| 191277 | 30WK 2D | 1.6 | М | | LSCS | RLJH | YES N | | | | FORMULA | | | YES | YES | | YES | | | | YES | | YES | | | YES YE | | | | | ENTEROCOCCI | 8DAYS | RECOVERED |
| 252757 252730 | 35WK 36WK | 1.24 | | 01-07-2023 01-08-2023 | LSCS LSCS | RUH RUH | YES N NO N | _ | | S YES | EBM+FORMULA EBM+FORMULA | NO NO | | YES NO | NO | NO NO | NO NO | YES | NO NO | | NO YES | | NO NO | | NO NO | NO N YES N | | | | | KLEBSIELLA | 14DAYS 16DAYS | RECOVERED RECOVERED |
| 254646 | 32WK | 1.6 | F | 04-07-2023 | ASSISTED VD | RUH | NO N | O N |) N | O YES | EBM+FORMULA | NO | YES | YES | YES | YES | NO | NO | NO | YES | YES | YES | YES | NO | NO | NO N | O YE | S YES | | | KLEBSIELLA | 18DAYS | RECOVERED |
| 241305 185767 | 36WK 38WK | 2.9 | M | 07-06-2023 08-01-2023 | NVD LSCS | OUTBORN | NO N | | | 0 NO 0 NO | DBF+EBM DBF+FORMULA | NO NO | NO NO | NO NO | YES | YES | NO | NO NO | | NO | NO YES | | | NO NO | | NO YE YES YE | | | | | KLEBSIELLA | 8DAYS 22DAYS | DAMA DEATH |
| 169790 | 38WK | 1.8 | M | | NVD | RUH | NO N | |) N | O NO | DBF+EBM | NO | NO | NO | YES | YES | NO | | | YES | NO | | | | | NO N | | | | | KLEBSIELLA | 14DAYS | RECOVERED |
| 159339 | 39WK | 2.08 | F M | | NVD | RLJH | YES N | | | 0 NO | DBF+FORMULA EBM+FORMULA | NO | | NO | YES | YES | NO | | | NO | YES | _ | _ | | | YES YE | | | | | KLEBSIELLA | 12DAYS | RECOVERED DAMA |
| 265709 243006 | 26WK 36WK | 0.9 1.8 | F | 01-09-2023 | NVD NVD | RUH RUH | NO N YES N | | | O YES | DBF+EBM | NO NO | YES | YES | YES | NO YES | NO NO | YES | _ | YES | NO YES | _ | YES | | NO NO | YES YE | | | | | CANDIDA KLEBSIELLA | 54DAYS 16DAYS | RECOVERED |
| 284793 | 36WK | 1.74 | М | 20-09-2023 | LSCS | OUTBORN | YES N | | | O NO | DBF+EBM | NO | YES | NO | NO | NO | NO | | | NO | NO | | | NO | NO | NO N | | | | | | 5DAYS | RECOVERED |
| 284205 168596 | 33WK | 1.84 | F M | | LSCS | RUH RUH | YES N NO N | |) N | O NO O YES | DBF+FORMULA EBM+FORMULA | NO NO | YES | NO YES | NO YES | NO YES | NO NO | NO YES | | NO NO | NO YES | | | | | NO N | | | | | KLERSIFLLA | 7DAYS 14DAYS | RECOVERED RECOVERED |
| 160367 | 35WK | 1.9 | F | 02-01-2023 | LSCS | R⊔H | NO N | ON C |) N | O NO | EBM+FORMULA | NO | | NO | NO | NO | NO | YES | YES | YES | YES | NO | NO | NO | NO | NO N | ON C |) NC |) NO | NEGATIVE | REEDSTEED | 20DAYS | RECOVERED |
| 234349 191174 | 36WK | 2.2 1.8 | F | 16-05-2023 21-02-2023 | LSCS | RUH RUH | YES N NO Y | _ | | O NO | EBM+FORMULA FBM+FORMULA | NO NO | YES | NO NO | YES | YES | NO YES | NO YES | | YES NO | NO YES | | NO YES | | NO NO | YES N | | | | | KLERSIELLA | 7DAYS 17DAYS | RECOVERED RECOVERED |
| 189662 | 39WK | 2.9 | M | 17-01-2023 | NVD | RUH | NO N | | | O YES | EBM+FORMULA | NO | | NO | YES | YES | NO | | | NO | YES | | | | | YES YE | | | | | KLEBSIELLA | 17DAYS 13DAYS | RECOVERED |
| 186204 | 35WK | 2.3 | F | 07-01-2023 | LSCS | R⊔H | NO Y | S NO |) N | O NO | EBM+FORMULA | NO | NO | NO | | NO | NO | YES | NO | NO | YES | NO | NO | NO | NO | NO N | O YE | S NO |) NO | NEGATIVE | | 7DAYS | RECOVERED |
| 251483 256498 | 29WKS 32WKS | 1.1 | M F | | NVD LSCS | RUH RUH | NO N YES N | | | O YES | EBM EBM+FORMULA | | NO YES | YES | YES | YES | NO NO | YES | | NO YES | YES NO | | | NO NO | | NO N | | | | | | 22DAYS 20DAYS | RECOVERED RECOVERED |
| 258133 | 34WKS | 1.8KG | М | 10-02-2024 | NVD | RUH | NO N | O N |) N | O NO | EBM+FORMULA | NO | NO | NO | | YES | NO | YES | NO | YES | NO | NO | NO | NO | NO | NO N | O NC |) NC |) NO | NEGATIVE | | 12DAYS | RECOVERED |
| 259380 259379 | 35WKS 34WKS | 1.9 1.8KG | M F | 15-07-2023 15-07-2023 | LSCS | RUH RUH | NO N | | | S NO | EBM+FORMULA FBM+FORMULA | NO NO | NO YES | NO NO | NO NO | NO NO | NO NO | NO NO | | NO YES | NO YES | | | | | YES N | | | | | CANDIDA CANDIDA | 14DAYS 16DAYS | RECOVERED RECOVERED |
| 268029 | 36WKS | 1.8 | M | 30-07-2023 | LSCS | RUH | YES N | | | S NO | EBM+FORMULA | NO | YES | NO | NO | NO | NO | | | NO | NO | | | | | NO N | | | | | CANDIDA | 10DAYS | RECOVERED |
| 259479 | 35WKS | 1.7 | F | | NVD | RUH | YES N | ON C |) N | 0 NO | EBM+FORMULA | | NO | NO | NO | YES | | NO | | | YES | | YES | | | NO N | | | | | CANDIDA | 18DAYS | RECOVERED |
| 295612 294995 | 36WKS 31WKS | 1.8 | F | 18-10-2023 17-10-2023 | LSCS LSCS | RUH RUH | NO N YES N | | | S NO O YES | EBM+FORMULA EBM+FORMULA | | NO NO | NO YES | YES | YES | NO NO | YES | | | NO NO | | | NO NO | | NO YE YES N | | | | | | 6DAYS 20DAYS | RECOVERED RECOVERED |
| 294187 | 35WK | 1.9 | М | 14-10-2023 | NVD | R⊔H | NO N | O N |) N | O NO | EBM+FORMULA | | YES | NO | YES | YES | NO | NO | NO | NO | YES | NO | NO | NO | NO | YES N | ON C |) NC |) NO | | | 16DAYS | RECOVERED |
| 292289 291670 | 36WK 32WKS | 2.1 1.3 | M | 09-10-2023 08-10-2023 | LSCS VACCUM | RLJH RLJH | NO Y | | | O NO | EBM+FORMULA NO | NO YES | YES | NO YES | NO YES | NO YES | NO | YES NO | | NO YES | NO YES | | | NO YES | | YES N | | | | | CONS KLEB OXYTYCA | 6DAYS 14DAYS | RECOVERED DAMA |
| 291273 | 31WKS | 1.3 | M | | LSCS | RUH | YES N | ON C |) N | O YES | EBM+FORMULA | NO | | NO | NO | NO | | YES | | | NO | NO | NO | NO | NO | NO N | | | | | REED OXITIES | 20DAYS | RECOVERED |
| 290437 286352 | 34WKS 40WKS | 1.4 3.6 | M | 05-10-2023 01-10-2023 | NVD FAILED VACCUM -LSCSrlj | RUH RUH | YES N NO N | | | O YES | EBM+FORMULA FBM+FORMULA | NO | | YES | YES | YES | NO | YES | | YES | YES NO | | | NO YES | | NO N | | | | | ECOLI | 10DAYS 12DAYS | RECOVERED RECOVERED |
| 287850 | 38WKS | 1.8 | F | | LSCS | RUH | NO Y | | | | EBM+FORMULA | NO NO | NO | NO | NO | YES | NO | | | NO | YES | | | | | YES N | | | | | ECOLI | 10DAYS | RECOVERED |
| 285319 | 37WKS | 2.3 | F | 23-09-2023 | NVD | RUH | NO N | | | 0 NO | EBM+FORMULA | NO | YES | NO | YES | NO | NO | | | NO | NO | | | | | NO N | | | | | | 8DAYS | RECOVERED |
| 287850 287744 | 37WKS 32WKS | 1.9 1.46 | F | 27-09-2023 27-09-2023 | LSCS NVD | RUH RUH | YES N NO N | | | S YES O YES | EBM+FORMULA FBM+FORMULA | NO NO | YES | NO YES | YES | NO NO | NO NO | YES | | NO NO | NO NO | | | | NO YES | YES N NO YE | | | | | | 5DAYS 16DAYS | RECOVERED RECOVERED |
| 285281 | 38WKS | 2.4 | М | 26-09-2023 | NVD | RUH | YES Y | S NO |) N | O NO | EBM+FORMULA | NO | YES | NO | YES | YES | NO | YES | NO | NO | YES | NO | NO | NO | NO | NO N | O YE | S NC |) NO | NEGATIVE | | 10DAYS | RECOVERED |
| 284205 280037 | 34wks 31wks | 2.02 | F | 19-09-2023 08-09-2023 | NVD NVD | RUH RUH | NO N | _ | | O NO O YES | EBM+FORMULA FBM | NO NO | YES | NO YES | NO YES | NO YES | NO YES | NO YES | YES | YES NO | YES | | NO YES | | NO NO | NO N YES N | _ | | | | | 7DAYS 18DAYS | RECOVERED RECOVERED |
| 386724 | 34WKS | 1.46 | F | 02-04-2024 | NVD | RUH | YES N | | | S YES | EBM+FORMULA | NO | NO | NO | NO | NO | NO | | | NO | NO | | | | | YES YE | | | | | | 14DAYS | DEATH |
| 358180 368813 | 29WKS 31WKS | 980GMS 1.24 | M | | NVD NVD | RLJH OUTBORN | NO N YES N | O N | | O YES | EBM FBM | | NO NO | YES | NO NO | | | YES | YES NO | NO NO | NO NO | | | YES | YES YES | YES YE | | | | | | 22DAYS 20DAYS | DEATH |
| 366098 | 37WKS | 2.12KG | M | | LSCS | RLIH | NO N | | | O YES | EBM+DBF | | NO | NO NO | NO | NO | | YES | | NO | | | | YES NO | | NO YE | | | | | | 7DAYS | RECOVERED |
| 368782 | 30WKS | 1.22KG | | | LSCS | RUH | YES N | | | O YES | | | NO | | | NO | | YES | NO | | YES | | | NO | | | _ | | | | | 18DAYS | RECOVERED |
| 372506 368121 | 38WKS 29WKS | 3.02KG 1.16KG | | 12-03-2024 04-03-2024 | LSCS LSCS | RUH RUH | NO Y | | | O YES | EBM+FORMULA EBM | NO NO | NO YES | NO YES | YES | YES NO | YES NO | NO YES | | NO NO | YES NO | | | | | NO YE YES YE | | | | | 1 | 10DAYS 20DAYS | DEATH DEATH |
| 364859 | 32WKS | 1KG | F | 01-03-2024 | NVD | R⊔H | NO N | O N |) N | O YES | EBM | NO | NO | YES | NO | NO | YES | YES | YES | NO | NO | NO | YES | YES | YES | NO YE | S YE | S NC |) YE | S NEGATIVE | | 14DAYS | DAMA |
| 347242 317719 | 32WKS 41WKS | 1.80KG 1.67KGS | | 29-02-2024 08-12-2023 | LSCS LSCS | RUH RUH | YES N | | | O YES | EBM+FORMULA EBM+FORMULA | NO NO | NO NO | NO NO | NO NO | NO NO | NO NO | NO NO | | | NO NO | | | NO NO | | NO N | | | | | 1 | 18DAYS 4DAYS | RECOVERED RECOVERED |
| 311742 | 37WKS | 1.6KG | М | 01-11-2023 | NVD | RUH | NO Y | S N |) YE | S YES | EBM+FORMULA | YES | YES | NO | NO | | NO | YES | YES | NO | NO | NO | NO | NO | NO | NO N | O NO |) NC |) NO | NEGATIVE | | 5DAYS | RECOVERED |
| 327631 340922 | 29WKS 30WKS | 950GMS 1.22KG | | 22-12-2023 17-01-2024 | NVD LSCS | RUH RUH | NO N | | | O YES | EBM EBM | NO NO | NO YES | YES | YES | YES NO | YES | YES | | NO NO | YES NO | | | | | YES N | | | | | ECOLI ACITINOBACTER | 28DAYS 22DAYS | RECOVERED RECOVERED |
| 339947 | 32WKS | 1.72 KG | | | LSCS | RUH | YES N | ON C |) N | O NO | EBM+FORMULA | | | NO | | NO | NO | | | NO | NO | NO | NO | NO | NO | NO N | | | | | ACITINOBACTER | 16DAYS | RECOVERED |
| 346175 | 39WKS | 2.74KG | F | 26-01-2024 | LSCS | RUH | NO N | ON C |) N | O NO | EBM+FORMULA | YES | NO | NO | | NO | NO | NO | NO | YES | NO | NO | NO | NO | NO | NO N | ON C |) NC |) NO | NEGATIVE | | 7DAYS | RECOVERED |
| 347828 358174 | 31WKS 40WKS | 1.02KG 2.74KG | F M | 30-01-2024 16-02-2024 | LSCS NVD | RLJH OUTBORN | YES N | | | O YES | EBM EBM+FORMULA | NO NO | | NO NO | YES NO | YES NO | YES | YES | NO NO | NO YES | YES NO | | | NO YES | | YES YE | | | | | ENTEROBACTER | 12DAYS 14DAYS | RECOVERED RECOVERED |
| 361888 | 30WKS | 1.58KG | М | 22-02-2024 | LSCS | R⊔H | NO N | O N |) N | O YES | EBM+FORMULA | NO | NO | NO | NO | NO | NO | YES | YES | NO | NO | NO | NO | NO | NO | NO N | O NO |) NC |) NO | NEGATIVE | | 18DAYS | RECOVERED |
| 327635 | 28WKS 29WKS | 980GMS 1.2KG | M | 03-02-2024 25-12-2023 | NVD LSCS | RLJH RLJH | NO N | | | O YES | EBM EBM | YES | NO YES | YES | YES | YES | YES | | | NO NO | NO YES | _ | | | | YES N | | | | | ECOLI ACITINOBACTER | 16DAYS 32DAYS | DEATH RECOVERED |
| 259380 | 31WKS | 1.6KG | М | 15-07-2023 | LSCS | RUH | YES N | O YE | S N | O YES | EBM | NO | YES | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO N | ON C |) NC |) NO | NEGATIVE | ACTINODACTER | 14DAYS | RECOVERED |
| 258133 | 34WKS 36WKS | 1.7KG 1.8KG | М | | LSCS | RUH RUH | YES N | ON C |) N | O YES | EBM+FORMULA FBM+FORMULA | NO | NO | NO NO | NO | NO NO | YES | | NO NO | NO | NO NO | | | | | NO N | | | | | ENTEROCOCCI | 12DAYS 14DAYS | RECOVERED |
| 268029 169790 | 36WKS 38WKS | 1.8KG 1.8KG | _ | 30-07-2023 03-12-2024 | LSCS NVD | RUH RUH | NO N YES Y | _ | _ | O NO | EBM+FORMULA EBM+FORMULA | | NO | | | NO NO | | NO NO | | | YES | | | NO YES | NO NO | | _ | | | | KLEBSIELLA | 14DAYS 16DAYS | RECOVERED RECOVERED |
| 326642 | 36WKS | 1.96KG | М | 22-12-2023 | LSCS | RUH | YES N | O N |) YE | S NO | EBM+FORMULA | NO | YES | NO | YES | YES | YES | NO | NO | NO | YES | NO | NO | YES | NO | NO N | O YE | S NO |) NO | NEGATIVE | | 4DAYS | RECOVERED |
| 324706 256498 | 34WKS 34WKS | 1.06KG 2.0KG | M F | | LSCS NVD | RUH RUH | NO N YES N | | | O YES | EBM EBM+FORMULA | NO NO | | NO NO | | | NO NO | YES | YES | YES NO | NO NO | YES NO | YES NO | NO NO | NO NO | YES N NO YE | | | | | 1 | 6DAYS 16DAYS | RECOVERED RECOVERED |
| 259379 | 33WKS | 1.04KG | F | 15-07-2023 | LSCS | RUH | NO N | O N |) N | O YES | EBM | YES | NO | NO | YES | YES | YES | YES | NO | NO | YES | YES | YES | NO . | YES | YES YE | S NO |) NC |) NO | NEGATIVE | | 10DAYS | RECOVERED |
| 401613 383036 | 34WKS 31WKS | 1.3KG 1.4KG | _ | 18-04-2024 28-03-2024 | NVD NVD | RUH RUH | NO N | | | O YES | | | | NO | | | | | | | | | | | | YES YE | | | | | 1 | 16DAYS 18DAYS | RECOVERED RECOVERED |
| 303U30 | STAALS | 1.410 | IVI | 20-03-2024 | INVU | NUT | YES N | - Ν(| , IN | U IES | EDIVITEURIVIULA | INU | 100 | YES | 1E2 | 152 | IVU | 100 | 152 | NU | 163 | INO | NU | INO | NU | INO N | J TE | , INC | - INC | NEGATIVE | 1 | TODATO | NECOVERED |

| ОНЮ | GESTATION | втит | GENDER | DOA | MODE OF DELIVERY | PLACE | PROM | MAS | INTRAPARTM FEVER | IUGR | CENTRAL LINE | FEEDING | UMBLICAL SEPSIS | CONJUCTIVITIS | APNEA | LETHARGY | REFUSAL OF FEEDS | WEAK CRY | TCHYPNEA | GRUNTING | SEIZURES | TEMPERATURE INSTABILITY | DISTENSION | VOMITING | BLEEDING | SCLEREMA | HYPOGLYCEMIA | AKI | THROMBOCYTOPENIA | MENINGITIS | MODS | CULTURE | ORGANISM | NICU STAY | OUTCOME |
|------------|-----------|--------|--------|------------|------------------|---------|------|-----|------------------|-------|--------------|-------------|-----------------|---------------|-------|----------|------------------|----------|----------|----------|----------|-------------------------|------------|----------|----------|----------|--------------|-----|------------------|------------|------|----------|------------|-----------|-----------|
| 398591 | 35WKS | 1.9KG | F | 15-04-2024 | LSCS | RUH | YES | NO | NO | NO N | NO E | EBM+FORMULA | NO | NO | NO | NO | | | | NO ' | | | YES | YES | NO | NO | YES | NO | NO | NO | NO | NEGATIVE | | 10DAYS | RECOVERED |
| 399356 | 37WKS | 1.5KG | M | 16-04-2024 | LSCS | OUTBORN | YES | YES | YES | YES Y | 'ES E | EBM+FORMULA | NO | NO | NO | NO | | | | NO I | | | NO | NO | YES | NO | NO | NO | YES | NO | NO | NEGATIVE | | 7DAYS | DAMA |
| 398618 | 36WKS | 1.8KG | M | 16-04-2024 | LSCS | OUTBORN | NO | NO | NO | NO N | NO E | EBM+FORMULA | NO | NO | NO | NO | | NO | | NO I | NO | | | | | NO | | NO | YES | NO | YES | NEGATIVE | | 8DAYS | DAMA |
| 23-10-2955 | 36WKS | 1.7KG | F | 01-04-2024 | LSCS | RLJH | YES | NO | NO | YES N | NO E | EBM+FORMULA | NO | YES | NO | NO | NO | YES | NO | NO I | NO | YES | NO | NO | YES | NO | NO | NO | YES | NO | YES | POSITIVE | KLEBSIELLA | 12DAYS | RECOVERED |
| 376397 | 31WKS | 1.38KG | F | 20-03-2024 | LSCS | RLJH | NO | NO | NO | NO Y | 'ES | EBM | NO | NO | YES | NO | | | | YES ' | YES | YES | YES | YES | NO | YES | YES | YES | NO | NO | NO | NEGATIVE | | 12DAYS | RECOVERED |
| 376398 | 31WKS | 1.1KG | F | 20-03-2024 | LSCS | R⊔H | YES | NO | NO | NO Y | 'ES | EBM | NO | NO | YES | NO | NO | NO | YES | NO I | NO | NO | YES | YES | NO | NO | YES | YES | NO | NO | NO | NEGATIVE | | 21DAYS | RECOVERED |
| 366813 | 37WKS | 1.9KG | M | 02-03-2024 | NVD | RUH | NO | NO | NO | NO Y | 'ES E | EBM+FORMULA | YES | YES | NO | NO | YES | NO | YES | NO I | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NEGATIVE | | 4DAYS | RECOVERED |
| 368786 | 2.4KG | 38WKS | F | 05-03-2024 | LSCS | RUH | NO | NO | NO | NO N | NO E | EBM+FORMULA | NO | NO | | YES | | | | NO | | | NO | NO | NO | NO | YES | NO | YES | NO | NO | NEGATIVE | | 7DAYS | RECOVERED |
| 35345 | 1.8KG | 32WKS | F | 26-01-2024 | LSCS | RUH | YES | NO | NO | NO N | 10 E | EBM+FORMULA | NO | NO | NO | NO | S | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NEGATIVE | | 3DAYS | RECOVERED |